|
G |
Dhrs11 |
dehydrogenase/reductase 11 |
increases reduction |
ISO |
DHRS11 protein results in increased reduction of Dehydrocholic Acid |
CTD |
PMID:30926317 |
|
NCBI chr10:69,698,214...69,708,294
Ensembl chr10:69,698,214...69,708,295
|
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
multiple interactions |
EXP |
[CYP2C11 protein results in increased metabolism of Lithocholic Acid] which results in increased chemical synthesis of 3-oxocholan-24-oic acid |
CTD |
PMID:18039809 |
|
NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions |
EXP |
[CYP3A2 protein results in increased metabolism of Lithocholic Acid] which results in increased chemical synthesis of 3-oxocholan-24-oic acid |
CTD |
PMID:18039809 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a23-3a1 |
cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 |
multiple interactions |
EXP |
[CYP3A23-3A1 protein results in increased metabolism of Lithocholic Acid] which results in increased chemical synthesis of 3-oxocholan-24-oic acid |
CTD |
PMID:18039809 |
|
NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030 Ensembl chr12:9,254,475...9,285,030
|
|
G |
Dhrs11 |
dehydrogenase/reductase 11 |
increases reduction |
ISO |
DHRS11 protein results in increased reduction of 3-oxocholan-24-oic acid |
CTD |
PMID:30926317 |
|
NCBI chr10:69,698,214...69,708,294
Ensembl chr10:69,698,214...69,708,295
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases activity |
ISO |
3-oxocholan-24-oic acid results in increased activity of NR1I2 protein |
CTD |
PMID:15708356 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Vdr |
vitamin D receptor |
increases activity |
ISO |
3-oxocholan-24-oic acid results in increased activity of VDR protein |
CTD |
PMID:15708356 |
|
NCBI chr 7:128,987,981...129,037,677
Ensembl chr 7:128,987,981...129,037,677
|
|
|
G |
Hsd11b1 |
hydroxysteroid 11-beta dehydrogenase 1 |
increases abundance |
ISO |
HSD11B1 gene mutant form results in increased abundance of 7-ketodeoxycholic acid |
CTD |
PMID:25061560 |
|
NCBI chr13:104,728,539...104,798,884
Ensembl chr13:104,728,539...104,788,687
|
|
|
G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
increases chemical synthesis multiple interactions |
ISO |
CYP27A1 protein results in increased chemical synthesis of 3-hydroxy-5-cholestenoic acid [CYP27A1 protein results in increased metabolism of Cholesterol] which results in increased chemical synthesis of 3-hydroxy-5-cholestenoic acid; [CYP27A1 protein results in increased oxidation of 27-hydroxycholesterol] which results in increased chemical synthesis of 3-hydroxy-5-cholestenoic acid |
CTD |
PMID:8078928 PMID:9215552 PMID:9660774 PMID:14622972 |
|
NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551
|
|
G |
Ncoa2 |
nuclear receptor coactivator 2 |
multiple interactions |
ISO |
3-hydroxy-5-cholestenoic acid affects the reaction [NR1H3 protein binds to NCOA2 protein] |
CTD |
PMID:11089551 |
|
NCBI chr 5:5,835,642...6,069,693
Ensembl chr 5:5,835,706...6,067,451
|
|
G |
Nr1h3 |
nuclear receptor subfamily 1, group H, member 3 |
multiple interactions |
ISO |
3-hydroxy-5-cholestenoic acid affects the reaction [NR1H3 protein binds to NCOA2 protein]; 3-hydroxy-5-cholestenoic acid binds to and results in increased activity of NR1H3 protein |
CTD |
PMID:11089551 |
|
NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722
|
|
|
G |
Hsd11b1 |
hydroxysteroid 11-beta dehydrogenase 1 |
increases reduction multiple interactions |
ISO |
HSD11B1 protein results in increased reduction of 7-ketolithocholic acid [HSD11B1 protein results in increased reduction of 7-ketolithocholic acid] which results in increased chemical synthesis of Chenodeoxycholic Acid; [HSD11B1 protein results in increased reduction of 7-ketolithocholic acid] which results in increased chemical synthesis of Ursodeoxycholic Acid |
CTD |
PMID:21453287 |
|
NCBI chr13:104,728,539...104,798,884
Ensembl chr13:104,728,539...104,788,687
|
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with Dietary Fats co-treated with Canrenoic Acid co-treated with isoquercitrin analog] results in increased expression of CAT mRNA |
CTD |
PMID:30298849 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cyba |
cytochrome b-245 alpha chain |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with Dietary Fats co-treated with Canrenoic Acid] results in increased expression of CYBA mRNA |
CTD |
PMID:30298849 |
|
NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721
|
|
G |
Hnrnpa2b1 |
heterogeneous nuclear ribonucleoprotein A2/B1 |
multiple interactions |
EXP |
Canrenoic Acid inhibits the reaction [Sodium, Dietary deficiency results in increased expression of HNRNPA2B1 mRNA] |
CTD |
PMID:23139218 |
|
NCBI chr 4:80,534,659...80,545,297
Ensembl chr 4:80,534,651...80,545,249
|
|
G |
Nr3c2 |
nuclear receptor subfamily 3, group C, member 2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with Dietary Fats co-treated with Canrenoic Acid co-treated with isoquercitrin analog] results in increased expression of NR3C2 mRNA |
CTD |
PMID:30298849 |
|
NCBI chr19:30,715,634...31,059,885
Ensembl chr19:30,715,648...31,059,885
|
|
G |
Pnpla2 |
patatin-like phospholipase domain containing 2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with Dietary Fats co-treated with Canrenoic Acid] results in increased expression of PNPLA2 mRNA |
CTD |
PMID:30298849 |
|
NCBI chr 1:196,552,723...196,557,805
Ensembl chr 1:196,552,723...196,557,805
|
|
G |
Poldip2 |
DNA polymerase delta interacting protein 2 |
multiple interactions |
EXP |
[Diethylnitrosamine co-treated with Dietary Fats co-treated with Canrenoic Acid] results in increased expression of POLDIP2 mRNA |
CTD |
PMID:30298849 |
|
NCBI chr10:63,407,237...63,417,605
Ensembl chr10:63,407,213...63,417,605
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions increases expression decreases expression |
ISO EXP |
7-hydroxytheonellasterol inhibits the reaction [Chenodeoxycholic Acid results in increased expression of ABCB11 mRNA]; [Chenodeoxycholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of ABCB11 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of ABCB11 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ABCB11 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of ABCB11 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ABCB11 mRNA; [pregna-4,17-diene-3,16-dione co-treated with Chenodeoxycholic Acid] results in increased expression of ABCB11 mRNA; Copper Sulfate inhibits the reaction [Chenodeoxycholic Acid results in increased expression of ABCB11 mRNA]; epigallocatechin gallate inhibits the reaction [Chenodeoxycholic Acid results in increased expression of ABCB11 mRNA]; LG 100268 inhibits the reaction [Chenodeoxycholic Acid results in increased expression of ABCB11 mRNA]; Zinc Sulfate inhibits the reaction [Copper Sulfate inhibits the reaction [Chenodeoxycholic Acid results in increased expression of ABCB11 mRNA]] Chenodeoxycholic Acid results in increased expression of ABCB11 mRNA; Chenodeoxycholic Acid results in increased expression of ABCB11 protein Chenodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in decreased expression of ABCB11 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Chenodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in decreased expression of ABCB11 mRNA]] Chenodeoxycholic Acid results in decreased expression of ABCB11 mRNA Chenodeoxycholic Acid inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of ABCB11 mRNA]; Chenodeoxycholic Acid inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of ABCB11 protein]; Chenodeoxycholic Acid promotes the reaction [Carbon Tetrachloride results in increased expression of ABCB11 mRNA]; epiallopregnanolone sulfate inhibits the reaction [Chenodeoxycholic Acid results in increased expression of ABCB11 mRNA]; NR1H4 protein promotes the reaction [Chenodeoxycholic Acid results in increased expression of ABCB11 mRNA] |
CTD |
PMID:12519787 PMID:12525500 PMID:14684751 PMID:16423920 PMID:17963371 PMID:19072826 PMID:22178739 PMID:22291955 PMID:22961653 PMID:25055961 PMID:25582706 PMID:25747392 PMID:26241054 PMID:27174168 PMID:27743861 PMID:32152650 PMID:32294204 PMID:32976922 PMID:33819548 More...
|
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ABCB1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCB1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
multiple interactions increases expression |
ISO EXP |
[[Chenodeoxycholic Acid binds to and results in increased activity of NR1H4 protein] which binds to ABCB4 promoter] which results in increased expression of ABCB4 mRNA; [Bezafibrate co-treated with Chenodeoxycholic Acid] results in increased expression of ABCB4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ABCB4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ABCB4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ABCB4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of ABCB4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCB4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ABCB4 mRNA [Chenodeoxycholic Acid co-treated with Ketoconazole] results in increased expression of ABCB4 mRNA Chenodeoxycholic Acid results in increased expression of ABCB4 mRNA |
CTD |
PMID:14527955 PMID:14623915 PMID:15588777 PMID:25582706 PMID:27174168 PMID:30985903 PMID:33819548 More...
|
|
NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of ABCC1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of ABCC1 mRNA; Chenodeoxycholic Acid inhibits the reaction [ABCC1 protein results in increased export of 2',7'-bis-(carboxypropyl)-5(6)-carboxyfluorescein] |
CTD |
PMID:16101123 PMID:33819548 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
multiple interactions increases expression affects expression |
EXP ISO |
ABCC2 protein affects the reaction [verlukast results in decreased secretion of Chenodeoxycholic Acid]; Chenodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in decreased expression of ABCC2 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Chenodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in decreased expression of ABCC2 mRNA]] Chenodeoxycholic Acid promotes the reaction [Carbon Tetrachloride results in increased expression of ABCC2 mRNA] [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of ABCC2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ABCC2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCC2 mRNA Chenodeoxycholic Acid results in increased expression of ABCC2 mRNA Chenodeoxycholic Acid affects the expression of ABCC2 mRNA |
CTD |
PMID:20888898 PMID:21262925 PMID:25055961 PMID:25582706 PMID:25747392 PMID:27743861 PMID:33819548 More...
|
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
increases expression multiple interactions |
EXP ISO |
Chenodeoxycholic Acid results in increased expression of ABCC3 mRNA [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ABCC3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of ABCC3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ABCC3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCC3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ABCC3 mRNA |
CTD |
PMID:20888898 PMID:25055961 PMID:25582706 PMID:27743861 PMID:32152650 PMID:33819548 More...
|
|
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
multiple interactions decreases expression |
ISO |
7-hydroxytheonellasterol inhibits the reaction [[Chenodeoxycholic Acid promotes the reaction [NR1H4 protein binds to ABCC4 promoter]] which results in decreased expression of ABCC4 mRNA]; 7-hydroxytheonellasterol inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein binds to ABCC4 promoter]]; 7-hydroxytheonellasterol inhibits the reaction [Chenodeoxycholic Acid results in decreased expression of ABCC4 mRNA]; [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein binds to ABCC4 promoter]] which results in decreased expression of ABCC4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of ABCC4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of ABCC4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of ABCC4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ABCC4 mRNA; Chenodeoxycholic Acid promotes the reaction [NR1H4 protein binds to ABCC4 promoter] |
CTD |
PMID:22291955 PMID:32152650 PMID:33819548 |
|
NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of ABCG2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of ABCG2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of ABCG2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of ABCG2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCG2 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Abcg5 |
ATP binding cassette subfamily G member 5 |
increases expression multiple interactions |
ISO |
Chenodeoxycholic Acid results in increased expression of ABCG5 mRNA [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ABCG5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ABCG5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ABCG5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ABCG5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCG5 mRNA |
CTD |
PMID:25055961 PMID:25582706 PMID:27174168 PMID:33819548 |
|
NCBI chr 6:9,965,118...9,990,563
Ensembl chr 6:9,965,118...9,990,563
|
|
G |
Abcg8 |
ATP binding cassette subfamily G member 8 |
increases expression multiple interactions |
ISO |
Chenodeoxycholic Acid results in increased expression of ABCG8 mRNA [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of ABCG8 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ABCG8 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ABCG8 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ABCG8 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ABCG8 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCG8 mRNA |
CTD |
PMID:25582706 PMID:27174168 PMID:33819548 |
|
NCBI chr 6:9,945,629...9,964,912
Ensembl chr 6:9,945,629...9,964,912
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
multiple interactions |
ISO |
Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of ACACA protein] |
CTD |
PMID:27773935 |
|
NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
|
|
G |
Acad11 |
acyl-CoA dehydrogenase family, member 11 |
decreases expression |
ISO |
Chenodeoxycholic Acid results in decreased expression of ACAD11 mRNA |
CTD |
PMID:27174168 |
|
NCBI chr 8:104,681,346...104,746,559
Ensembl chr 8:104,681,396...104,746,560
|
|
G |
Acads |
acyl-CoA dehydrogenase short chain |
multiple interactions |
ISO |
Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in decreased expression of ACADS mRNA] |
CTD |
PMID:27773935 |
|
NCBI chr12:41,493,650...41,502,897
Ensembl chr12:41,493,626...41,502,898
|
|
G |
Acadsb |
acyl-CoA dehydrogenase, short/branched chain |
decreases expression |
ISO |
Chenodeoxycholic Acid results in decreased expression of ACADSB mRNA |
CTD |
PMID:27174168 |
|
NCBI chr 1:186,188,939...186,227,796
Ensembl chr 1:186,188,987...186,230,379
|
|
G |
Acat1 |
acetyl-CoA acetyltransferase 1 |
decreases expression |
ISO |
Chenodeoxycholic Acid results in decreased expression of ACAT1 mRNA |
CTD |
PMID:27174168 |
|
NCBI chr 8:53,979,813...54,008,861
Ensembl chr 8:53,979,813...54,008,855
|
|
G |
Acsl1 |
acyl-CoA synthetase long-chain family member 1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ACSL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ACSL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ACSL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ACSL1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr16:45,755,246...45,821,541
Ensembl chr16:45,755,254...45,821,541
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
ISO |
Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of ACTA2 mRNA] |
CTD |
PMID:27773935 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Adgrg1 |
adhesion G protein-coupled receptor G1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of ADGRG1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of ADGRG1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of ADGRG1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of ADGRG1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of ADGRG1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ADGRG1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr19:10,003,963...10,041,122
Ensembl chr19:10,003,975...10,041,108
|
|
G |
Adh1c |
alcohol dehydrogenase 1C (class I), gamma polypeptide |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of ADH1C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ADH1C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ADH1C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ADH1C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ADH1C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ADH1C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ADH1C mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 2:226,797,303...226,808,892
Ensembl chr 2:226,797,303...226,808,892
|
|
G |
Adh4 |
alcohol dehydrogenase 4 (class II), pi polypeptide |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of ADH4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ADH4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ADH4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ADH4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ADH4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ADH4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ADH4 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 2:226,948,717...226,966,747
Ensembl chr 2:226,947,466...226,987,591
|
|
G |
Adh6 |
alcohol dehydrogenase 6 (class V) |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of ADH6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ADH6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ADH6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ADH6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ADH6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ADH6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ADH6 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 2:226,903,208...226,934,564
Ensembl chr 2:226,903,250...226,934,534
|
|
G |
Ahr |
aryl hydrocarbon receptor |
decreases expression increases secretion multiple interactions |
ISO |
Chenodeoxycholic Acid results in decreased expression of AHR mRNA AHR gene mutant form results in increased secretion of Chenodeoxycholic Acid [AHR gene mutant form affects the susceptibility to Tetrachlorodibenzodioxin] which results in decreased secretion of Chenodeoxycholic Acid |
CTD |
PMID:27174168 PMID:29452137 PMID:32679164 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Akr1a1 |
aldo-keto reductase family 1 member A1 |
multiple interactions |
ISO |
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR1A1 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 5:130,092,945...130,130,277
Ensembl chr 5:130,092,732...130,113,674
|
|
G |
Akr1c1 |
aldo-keto reductase family 1, member C1 |
decreases expression |
ISO |
Chenodeoxycholic Acid results in decreased expression of AKR1C1 mRNA |
CTD |
PMID:27174168 |
|
NCBI chr17:65,810,474...65,837,385
Ensembl chr17:65,810,475...65,837,326
|
|
G |
Akr1c2 |
aldo-keto reductase family 1, member C2 |
affects binding decreases activity |
ISO |
Chenodeoxycholic Acid binds to AKR1C2 protein Chenodeoxycholic Acid results in decreased activity of AKR1C2 protein |
CTD |
PMID:8486699 PMID:8573067 |
|
NCBI chr17:65,759,778...65,808,013
Ensembl chr17:65,759,788...65,775,764
|
|
G |
Akr1d1 |
aldo-keto reductase family 1, member D1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of AKR1D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of AKR1D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of AKR1D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of AKR1D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of AKR1D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of AKR1D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR1D1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 4:66,154,246...66,187,505
Ensembl chr 4:66,154,248...66,186,372
|
|
G |
Akr7a2 |
aldo-keto reductase family 7, member A2 |
multiple interactions |
ISO |
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of AKR7A2 mRNA |
CTD |
PMID:32152650 PMID:33819548 |
|
NCBI chr 5:151,552,375...151,560,914
Ensembl chr 5:151,552,343...151,560,909
|
|
G |
Akr7a3 |
aldo-keto reductase family 7 member A3 |
decreases expression multiple interactions |
ISO |
Chenodeoxycholic Acid results in decreased expression of AKR7A3 mRNA [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of AKR7A3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of AKR7A3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of AKR7A3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of AKR7A3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA |
CTD |
PMID:27174168 PMID:32152650 PMID:33819548 |
|
NCBI chr 5:151,590,968...151,601,394
Ensembl chr 5:151,584,479...151,601,394
|
|
G |
Alb |
albumin |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of ALB mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ALB mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ALB mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ALB mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ALB mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ALB mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ALB mRNA |
CTD |
PMID:33819548 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Alpp |
alkaline phosphatase, placental |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of ALPP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ALPP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ALPP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ALPP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ALPP mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 9:87,765,846...87,768,606
Ensembl chr 9:87,765,860...87,768,606
|
|
G |
Ampd3 |
adenosine monophosphate deaminase 3 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of AMPD3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of AMPD3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of AMPD3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of AMPD3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of AMPD3 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 1:164,884,823...164,929,899
Ensembl chr 1:164,885,320...164,929,887
|
|
G |
Angptl3 |
angiopoietin-like 3 |
decreases expression multiple interactions |
ISO |
Chenodeoxycholic Acid results in decreased expression of ANGPTL3 mRNA Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of ANGPTL3 mRNA] |
CTD |
PMID:27174168 PMID:27773935 |
|
NCBI chr 5:113,703,007...113,710,044
Ensembl chr 5:113,703,012...113,709,957
|
|
G |
Aox1 |
aldehyde oxidase 1 |
multiple interactions |
ISO |
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AOX1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AOX1 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 9:59,579,621...59,658,772
Ensembl chr 9:59,579,649...59,658,770
|
|
G |
Apoa1 |
apolipoprotein A1 |
decreases expression multiple interactions |
ISO |
Chenodeoxycholic Acid results in decreased expression of APOA1 protein [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of APOA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of APOA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of APOA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of APOA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of APOA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of APOA1 mRNA |
CTD |
PMID:19445040 PMID:33819548 |
|
NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035
|
|
G |
Apoa4 |
apolipoprotein A4 |
decreases expression |
ISO |
Chenodeoxycholic Acid results in decreased expression of APOA4 mRNA |
CTD |
PMID:27174168 |
|
NCBI chr 8:46,539,083...46,541,464
Ensembl chr 8:46,539,082...46,541,469
|
|
G |
Apoc2 |
apolipoprotein C2 |
multiple interactions |
ISO |
Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in decreased expression of APOC2 mRNA] |
CTD |
PMID:27773935 |
|
NCBI chr 1:79,329,429...79,334,397
Ensembl chr 1:79,329,428...79,334,476
|
|
G |
Apoc3 |
apolipoprotein C3 |
multiple interactions |
ISO |
Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of APOC3 mRNA] |
CTD |
PMID:27773935 |
|
NCBI chr 8:46,531,478...46,533,658
Ensembl chr 8:46,531,478...46,533,583
|
|
G |
Apoc4 |
apolipoprotein C4 |
decreases expression |
ISO |
Chenodeoxycholic Acid results in decreased expression of APOC4 mRNA |
CTD |
PMID:27174168 |
|
NCBI chr 1:79,335,745...79,339,942
Ensembl chr 1:79,335,745...79,339,981
|
|
G |
Apoh |
apolipoprotein H |
decreases expression |
ISO |
Chenodeoxycholic Acid results in decreased expression of APOH mRNA |
CTD |
PMID:27174168 |
|
NCBI chr10:93,342,435...93,356,334
Ensembl chr10:93,310,977...93,356,329
|
|
G |
Apom |
apolipoprotein M |
decreases expression |
ISO |
Chenodeoxycholic Acid results in decreased expression of APOM mRNA |
CTD |
PMID:27174168 |
|
NCBI chr20:3,690,950...3,693,550
Ensembl chr20:3,688,413...3,693,550
|
|
G |
Atf4 |
activating transcription factor 4 |
multiple interactions |
ISO |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ATF4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
|
|
G |
Atf6 |
activating transcription factor 6 |
multiple interactions |
ISO |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177
|
|
G |
Atg7 |
autophagy related 7 |
multiple interactions |
ISO |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 4:147,718,663...147,925,656
Ensembl chr 4:147,718,752...147,925,593
|
|
G |
Atp8b1 |
ATPase phospholipid transporting 8B1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ATP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ATP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ATP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ATP8B1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr18:58,016,382...58,157,213
Ensembl chr18:58,018,268...58,157,396
|
|
G |
Baat |
bile acid CoA:amino acid N-acyltransferase |
decreases expression multiple interactions |
ISO |
Chenodeoxycholic Acid results in decreased expression of BAAT mRNA [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of BAAT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of BAAT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of BAAT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of BAAT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of BAAT mRNA |
CTD |
PMID:27174168 PMID:33819548 |
|
NCBI chr 5:63,851,668...63,860,641
Ensembl chr 5:63,850,705...63,860,685
|
|
G |
Bach1 |
BTB domain and CNC homolog 1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of BACH1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr11:26,939,429...26,974,876
Ensembl chr11:26,939,480...26,972,447
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression |
EXP |
Chenodeoxycholic Acid results in increased expression of BAX mRNA |
CTD |
PMID:17881359 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of BCL2L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of BCL2L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of BCL2L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of BCL2L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of BCL2L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of BCL2L1 mRNA Chenodeoxycholic Acid promotes the reaction [Carbon Tetrachloride results in decreased expression of BCL2L1 mRNA] |
CTD |
PMID:25747392 PMID:33819548 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479 Ensembl chr 1:141,253,523...141,303,479
|
|
G |
Cacna2d1 |
calcium voltage-gated channel auxiliary subunit alpha2delta 1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CACNA2D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CACNA2D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CACNA2D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of CACNA2D1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 4:18,950,611...19,374,969
Ensembl chr 4:18,951,002...19,374,969
|
|
G |
Casp3 |
caspase 3 |
increases activity multiple interactions |
ISO |
Chenodeoxycholic Acid results in increased activity of CASP3 protein Chenodeoxycholic Acid results in increased cleavage of and results in increased activity of CASP3 protein |
CTD |
PMID:16573382 PMID:19054763 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
multiple interactions increases activity |
ISO |
[Chenodeoxycholic Acid co-treated with ursodoxicoltaurine] results in increased activity of CASP9 protein; Chenodeoxycholic Acid results in increased cleavage of and results in increased activity of CASP9 protein Chenodeoxycholic Acid results in increased activity of CASP9 protein |
CTD |
PMID:14976352 PMID:19054763 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CAT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CAT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CAT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of CAT mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA |
CTD |
PMID:32152650 PMID:33819548 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cbr1 |
carbonyl reductase 1 |
multiple interactions |
ISO |
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CBR1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CBR1 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr11:32,860,571...32,862,981
Ensembl chr11:32,908,950...32,911,393 Ensembl chr11:32,908,950...32,911,393 Ensembl chr11:32,908,950...32,911,393
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions increases expression |
ISO |
Chenodeoxycholic Acid affects the reaction [alisol A 24-acetate inhibits the reaction [[Choline deficiency co-treated with Methionine deficiency] results in increased expression of CCL2 mRNA]]; Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of CCL2 mRNA]; EGR1 promotes the reaction [Chenodeoxycholic Acid results in increased expression of CCL2 mRNA] |
CTD |
PMID:21224055 PMID:27773935 PMID:29883724 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl20 |
C-C motif chemokine ligand 20 |
increases expression |
ISO |
Chenodeoxycholic Acid results in increased expression of CCL20 mRNA |
CTD |
PMID:21224055 |
|
NCBI chr 9:84,389,031...84,391,629
Ensembl chr 9:84,388,904...84,391,629
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
increases expression |
ISO |
Chenodeoxycholic Acid results in increased expression of CCL3 mRNA |
CTD |
PMID:21224055 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions increases expression |
ISO |
Bezafibrate inhibits the reaction [Chenodeoxycholic Acid results in increased expression of CCL5 mRNA]; Bezafibrate inhibits the reaction [Chenodeoxycholic Acid results in increased expression of CCL5 protein]; Fenofibrate inhibits the reaction [Chenodeoxycholic Acid results in increased expression of CCL5 mRNA]; Fenofibrate inhibits the reaction [Chenodeoxycholic Acid results in increased expression of CCL5 protein] Chenodeoxycholic Acid results in increased expression of CCL5 mRNA; Chenodeoxycholic Acid results in increased expression of CCL5 protein |
CTD |
PMID:12126966 PMID:21224055 |
|
NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ccl7 |
C-C motif chemokine ligand 7 |
multiple interactions increases expression |
ISO |
EGR1 promotes the reaction [Chenodeoxycholic Acid results in increased expression of CCL7 mRNA] |
CTD |
PMID:21224055 |
|
NCBI chr10:67,016,446...67,018,296
Ensembl chr10:67,016,446...67,018,303
|
|
G |
Ccnb1 |
cyclin B1 |
multiple interactions |
ISO |
Chenodeoxycholic Acid promotes the reaction [Carbon Tetrachloride results in increased expression of CCNB1 mRNA] |
CTD |
PMID:25747392 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
ISO |
Chenodeoxycholic Acid promotes the reaction [Carbon Tetrachloride results in increased expression of CCND1 mRNA] |
CTD |
PMID:25747392 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccr2 |
C-C motif chemokine receptor 2 |
multiple interactions |
ISO |
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CCR2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CCR2 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 8:123,734,465...123,742,483
Ensembl chr 8:123,734,430...123,742,100
|
|
G |
Cd36 |
CD36 molecule |
multiple interactions |
ISO |
Chenodeoxycholic Acid inhibits the reaction [tris(chloroethyl)phosphate results in increased expression of CD36 mRNA] |
CTD |
PMID:35780845 |
|
NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
affects localization |
ISO |
Chenodeoxycholic Acid affects the localization of CDKN1B protein |
CTD |
PMID:20818264 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cdx2 |
caudal type homeo box 2 |
increases expression |
ISO |
Chenodeoxycholic Acid results in increased expression of CDX2 mRNA |
CTD |
PMID:20818264 |
|
NCBI chr12:7,726,798...7,733,142
Ensembl chr12:7,726,798...7,733,142
|
|
G |
Chi3l1 |
chitinase 3 like 1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CHI3L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of CHI3L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CHI3L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CHI3L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of CHI3L1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr13:45,641,802...45,649,787
Ensembl chr13:45,641,802...45,649,787
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
decreases expression multiple interactions |
EXP ISO |
Chenodeoxycholic Acid results in decreased expression of COL1A1 mRNA Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of COL1A1 mRNA] |
CTD |
PMID:15980055 PMID:27773935 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Col1a2 |
collagen type I alpha 2 chain |
multiple interactions |
ISO |
Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of COL1A2 mRNA] |
CTD |
PMID:27773935 |
|
NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867
|
|
G |
Coro1a |
coronin 1A |
multiple interactions decreases expression |
ISO |
[Chenodeoxycholic Acid co-treated with Tretinoin] results in decreased expression of CORO1A mRNA Chenodeoxycholic Acid results in decreased expression of CORO1A mRNA |
CTD |
PMID:16040207 |
|
NCBI chr 1:181,295,561...181,300,566
Ensembl chr 1:181,295,562...181,300,534
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
multiple interactions |
ISO |
Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in decreased expression of CPT1A mRNA] |
CTD |
PMID:27773935 |
|
NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Csf1 |
colony stimulating factor 1 |
multiple interactions |
ISO |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of CSF1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of CSF1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA |
CTD |
PMID:32152650 PMID:33819548 |
|
NCBI chr 2:195,377,215...195,396,608
Ensembl chr 2:195,377,215...195,411,704
|
|
G |
Csf2 |
colony stimulating factor 2 |
multiple interactions increases expression |
ISO |
EGR1 promotes the reaction [Chenodeoxycholic Acid results in increased expression of CSF2 mRNA] |
CTD |
PMID:21224055 |
|
NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199
|
|
G |
Csf3 |
colony stimulating factor 3 |
increases expression |
ISO |
Chenodeoxycholic Acid results in increased expression of CSF3 mRNA |
CTD |
PMID:21224055 |
|
NCBI chr10:83,660,787...83,664,569
Ensembl chr10:83,661,207...83,663,603
|
|
G |
Cth |
cystathionine gamma-lyase |
multiple interactions |
EXP |
chenodeoxycholic acid inhibits the reaction [Carbon Tetrachloride decreases expression and activity of cystathionine gamma-lyase in rat liver] |
RGD |
PMID:19418582 |
RGD:15042868 |
NCBI chr 2:246,975,888...247,002,234
Ensembl chr 2:246,975,894...247,002,234
|
|
G |
Ctnnb1 |
catenin beta 1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CTNNB1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CTNNB1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Cttn |
cortactin |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of CTTN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CTTN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of CTTN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of CTTN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of CTTN mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 1:199,599,710...199,635,254
Ensembl chr 1:199,599,710...199,635,164
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
increases expression |
ISO |
Chenodeoxycholic Acid results in increased expression of CXCL10 mRNA |
CTD |
PMID:21224055 |
|
NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975
|
|
G |
Cxcl11 |
C-X-C motif chemokine ligand 11 |
increases expression |
ISO |
Chenodeoxycholic Acid results in increased expression of CXCL11 mRNA |
CTD |
PMID:21224055 |
|
NCBI chr14:15,689,432...15,692,207
Ensembl chr14:15,689,424...15,692,271
|
|
G |
Cxcl16 |
C-X-C motif chemokine ligand 16 |
increases expression |
ISO |
Chenodeoxycholic Acid results in increased expression of CXCL16 mRNA |
CTD |
PMID:21224055 |
|
NCBI chr10:55,166,721...55,171,316
Ensembl chr10:55,166,723...55,171,592
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
increases expression multiple interactions |
ISO |
Chenodeoxycholic Acid results in increased expression of CXCL2 mRNA; Chenodeoxycholic Acid results in increased expression of CXCL2 protein EGR1 protein promotes the reaction [Chenodeoxycholic Acid results in increased expression of CXCL2 mRNA]; EGR1 protein promotes the reaction [Chenodeoxycholic Acid results in increased expression of CXCL2 protein] |
CTD |
PMID:21224055 |
|
NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
increases expression |
ISO |
Chenodeoxycholic Acid results in increased expression of CXCL1 mRNA |
CTD |
PMID:21224055 |
|
NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511
|
|
G |
Cyld |
CYLD lysine 63 deubiquitinase |
multiple interactions |
ISO |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA |
CTD |
PMID:32152650 |
|
NCBI chr19:18,310,632...18,373,696
Ensembl chr19:18,314,019...18,373,658
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
decreases expression multiple interactions |
ISO |
Chenodeoxycholic Acid results in decreased expression of CYP17A1 mRNA NR1H4 protein promotes the reaction [Chenodeoxycholic Acid results in decreased expression of CYP17A1 mRNA] |
CTD |
PMID:22961653 |
|
NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
decreases expression multiple interactions |
ISO |
Chenodeoxycholic Acid results in decreased expression of CYP1A1 mRNA [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of CYP1A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of CYP1A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP1A1 mRNA |
CTD |
PMID:27174168 PMID:33819548 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
decreases expression multiple interactions |
ISO |
Chenodeoxycholic Acid results in decreased expression of CYP1A2 mRNA [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of CYP1A2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP1A2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CYP1A2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of CYP1A2 mRNA |
CTD |
PMID:27174168 PMID:33819548 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
decreases expression multiple interactions |
EXP ISO |
Chenodeoxycholic Acid results in decreased expression of CYP27A1 mRNA Chenodeoxycholic Acid inhibits the reaction [tris(chloroethyl)phosphate results in decreased expression of CYP27A1 mRNA]; Chenodeoxycholic Acid inhibits the reaction [tris(chloroethyl)phosphate results in decreased expression of CYP27A1 protein] [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CYP27A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP27A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP27A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CYP27A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of CYP27A1 mRNA |
CTD |
PMID:7832767 PMID:25582706 PMID:33819548 PMID:35780845 |
|
NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551
|
|
G |
Cyp2a1 |
cytochrome P450, family 2, subfamily a, polypeptide 1 |
decreases activity |
EXP |
Chenodeoxycholic Acid results in decreased activity of CYP2A1 protein |
CTD |
PMID:8889968 |
|
NCBI chr 1:82,231,611...82,244,887
Ensembl chr 1:82,231,611...82,244,887
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
multiple interactions |
ISO |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP2B6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP2B6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of CYP2B6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA |
CTD |
PMID:32152650 PMID:33819548 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
decreases activity multiple interactions |
EXP ISO |
Chenodeoxycholic Acid results in decreased activity of CYP2C11 protein [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP2C18 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP2C18 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CYP2C18 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of CYP2C18 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP2C18 mRNA |
CTD |
PMID:8889968 PMID:33819548 |
|
NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066
|
|
G |
Cyp2c6 |
cytochrome P450, family 2, subfamily C, polypeptide 6 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CYP2C19 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP2C19 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP2C19 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CYP2C19 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of CYP2C19 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2C19 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
decreases expression multiple interactions |
ISO |
Chenodeoxycholic Acid results in decreased expression of CYP2C8 mRNA [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CYP2C8 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP2C8 mRNA |
CTD |
PMID:27174168 PMID:33819548 |
|
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
decreases expression |
ISO |
Chenodeoxycholic Acid results in decreased expression of CYP2E1 mRNA |
CTD |
PMID:27174168 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions increases hydroxylation decreases expression decreases activity |
EXP ISO |
[CYP3A23-3A1 gene mutant form co-treated with CYP3A2 gene mutant form] results in increased abundance of Chenodeoxycholic Acid; Chenodeoxycholic Acid inhibits the reaction [Calcitriol results in increased expression of CYP3A2 mRNA] CYP3A4 protein results in increased hydroxylation of Chenodeoxycholic Acid Chenodeoxycholic Acid results in decreased expression of CYP3A4 mRNA [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP3A4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP3A4 mRNA; [CYP3A4 protein results in increased hydroxylation of Chenodeoxycholic Acid] which results in increased abundance of muricholic acid; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP3A4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP3A4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP3A4 mRNA; Chenodeoxycholic Acid promotes the reaction [CYP3A4 protein results in increased oxidation of 7-benzyloxy-4-trifluoromethylcoumarin] Chenodeoxycholic Acid results in decreased activity of CYP3A2 protein |
CTD |
PMID:8889968 PMID:19299527 PMID:20006981 PMID:27174168 PMID:32152650 PMID:33819548 PMID:34461081 PMID:36473578 More...
|
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a23-3a1 |
cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 |
multiple interactions increases expression |
EXP |
[CYP3A23-3A1 gene mutant form co-treated with CYP3A2 gene mutant form] results in increased abundance of Chenodeoxycholic Acid; Chenodeoxycholic Acid inhibits the reaction [Calcitriol results in increased expression of CYP3A23-3A1 mRNA]; Chenodeoxycholic Acid inhibits the reaction [Lithocholic Acid results in increased expression of CYP3A23-3A1 mRNA] Chenodeoxycholic Acid results in increased expression of CYP3A23-3A1 mRNA |
CTD |
PMID:20006981 PMID:34461081 |
|
NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030 Ensembl chr12:9,254,475...9,285,030
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP3A5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP3A5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CYP3A5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP3A5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP3A5 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
multiple interactions decreases expression |
ISO EXP |
Chenodeoxycholic Acid inhibits the reaction [tris(chloroethyl)phosphate results in decreased expression of CYP7A1 mRNA]; Chenodeoxycholic Acid promotes the reaction [Carbon Tetrachloride results in decreased expression of CYP7A1 mRNA]; NR1H4 mutant form inhibits the reaction [Chenodeoxycholic Acid results in decreased expression of CYP7A1 mRNA] [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [Chenodeoxycholic Acid analog binds to and results in increased activity of NR1H4 protein] which results in decreased expression of CYP7A1 mRNA; [Chenodeoxycholic Acid binds to and results in increased activity of NR1H4 protein] which results in decreased expression of CYP7A1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CYP7A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP7A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP7A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of CYP7A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA [Chenodeoxycholic Acid co-treated with Ketoconazole] results in decreased expression of CYP7A1 mRNA; [Chenodeoxycholic Acid results in increased expression of FGF19 protein] which results in decreased expression of CYP7A1 protein |
CTD |
PMID:17963371 PMID:19072826 PMID:20671298 PMID:20835427 PMID:25055961 PMID:25582706 PMID:25747392 PMID:27174168 PMID:30985903 PMID:32152650 PMID:33819548 PMID:35780845 More...
|
|
NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
|
|
G |
Cyp7b1 |
cytochrome P450 family 7 subfamily B member 1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CYP7B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP7B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP7B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CYP7B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of CYP7B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP7B1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 2:100,502,791...100,669,713
Ensembl chr 2:100,502,791...100,669,698
|
|
G |
Cyp8b1 |
cytochrome P450 family 8 subfamily B member 1 |
decreases expression multiple interactions |
ISO |
Chenodeoxycholic Acid results in decreased expression of CYP8B1 mRNA [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CYP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CYP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of CYP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP8B1 mRNA Chenodeoxycholic Acid inhibits the reaction [tris(chloroethyl)phosphate results in decreased expression of CYP8B1 mRNA]; Chenodeoxycholic Acid promotes the reaction [1-Naphthylisothiocyanate results in decreased expression of CYP8B1 mRNA]; Chenodeoxycholic Acid promotes the reaction [1-Naphthylisothiocyanate results in decreased expression of CYP8B1 protein]; Chenodeoxycholic Acid promotes the reaction [Carbon Tetrachloride results in decreased expression of CYP8B1 mRNA] |
CTD |
PMID:25055961 PMID:25582706 PMID:25747392 PMID:32976922 PMID:33819548 PMID:35780845 More...
|
|
NCBI chr 8:121,578,123...121,580,093
Ensembl chr 8:121,557,062...121,580,166
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions |
ISO |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Dnajb1 |
DnaJ heat shock protein family (Hsp40) member B1 |
multiple interactions |
ISO |
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB1 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr19:24,522,731...24,526,419
Ensembl chr19:24,522,717...24,526,458
|
|
G |
Dnajb11 |
DnaJ heat shock protein family (Hsp40) member B11 |
multiple interactions |
ISO |
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB11 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB11 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr11:78,151,750...78,168,259
Ensembl chr11:78,150,429...78,180,407
|
|
G |
Dnajb6 |
DnaJ heat shock protein family (Hsp40) member B6 |
multiple interactions |
ISO |
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB6 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 4:5,452,683...5,556,679
Ensembl chr 4:5,452,683...5,556,659
|
|
G |
Dnajb9 |
DnaJ heat shock protein family (Hsp40) member B9 |
multiple interactions |
ISO |
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of DNAJB9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of DNAJB9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of DNAJB9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of DNAJB9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of DNAJB9 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB9 mRNA |
CTD |
PMID:32152650 PMID:33819548 |
|
NCBI chr 6:61,270,385...61,276,795
Ensembl chr 6:61,269,913...61,275,063
|
|
G |
Dnajc1 |
DnaJ heat shock protein family (Hsp40) member C1 |
multiple interactions |
ISO |
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC1 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr17:80,955,209...81,112,025
Ensembl chr17:80,955,237...81,111,988
|
|
G |
Dnajc10 |
DnaJ heat shock protein family (Hsp40) member C10 |
multiple interactions |
ISO |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of DNAJC10 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of DNAJC10 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of DNAJC10 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of DNAJC10 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA |
CTD |
PMID:32152650 PMID:33819548 |
|
NCBI chr 3:65,232,031...65,272,732
Ensembl chr 3:65,232,697...65,272,719
|
|
G |
Dnajc12 |
DnaJ heat shock protein family (Hsp40) member C12 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of DNAJC12 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of DNAJC12 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of DNAJC12 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr20:25,246,744...25,267,508
Ensembl chr20:25,223,144...25,267,521
|
|
G |
Dnajc16 |
DnaJ heat shock protein family (Hsp40) member C16 |
multiple interactions |
ISO |
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC16 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 5:154,073,372...154,106,246
Ensembl chr 5:154,075,261...154,106,136
|
|
G |
Dnajc18 |
DnaJ heat shock protein family (Hsp40) member C18 |
multiple interactions |
ISO |
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC18 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of DNAJC18 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of DNAJC18 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC18 mRNA |
CTD |
PMID:32152650 PMID:33819548 |
|
NCBI chr18:27,269,350...27,303,453
Ensembl chr18:27,269,355...27,298,344
|
|
G |
Dnajc19 |
DnaJ heat shock protein family (Hsp40) member C19 |
multiple interactions |
ISO |
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC19 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC19 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 2:116,923,272...116,945,312
Ensembl chr 2:116,923,272...116,945,264
|
|
G |
Dnajc21 |
DnaJ heat shock protein family (Hsp40) member C21 |
multiple interactions |
ISO |
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC21 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC21 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 2:59,419,507...59,446,746
Ensembl chr 2:59,419,510...59,446,752
|
|
G |
Dnajc3 |
DnaJ heat shock protein family (Hsp40) member C3 |
multiple interactions |
ISO |
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC3 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr15:96,025,605...96,068,585
Ensembl chr15:96,025,624...96,065,181
|
|
G |
Dnajc6 |
DnaJ heat shock protein family (Hsp40) member C6 |
multiple interactions |
ISO |
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC6 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 5:116,120,069...116,283,448
Ensembl chr 5:116,119,676...116,283,448
|
|
G |
Dnajc9 |
DnaJ heat shock protein family (Hsp40) member C9 |
multiple interactions |
ISO |
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of DNAJC9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of DNAJC9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of DNAJC9 mRNA |
CTD |
PMID:32152650 PMID:33819548 |
|
NCBI chr15:3,923,842...3,928,118
Ensembl chr15:3,923,268...3,928,118
|
|
G |
Edn1 |
endothelin 1 |
decreases expression |
EXP |
Chenodeoxycholic Acid results in decreased expression of EDN1 mRNA |
CTD |
PMID:16357303 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Egr1 |
early growth response 1 |
multiple interactions increases expression |
ISO |
EGR1 promotes the reaction [Chenodeoxycholic Acid results in increased expression of CCL2 mRNA]; EGR1 promotes the reaction [Chenodeoxycholic Acid results in increased expression of CCL7 mRNA]; EGR1 promotes the reaction [Chenodeoxycholic Acid results in increased expression of CSF2 mRNA]; EGR1 promotes the reaction [Chenodeoxycholic Acid results in increased expression of SERPINE1 mRNA]; EGR1 protein promotes the reaction [Chenodeoxycholic Acid results in increased expression of CXCL2 mRNA]; EGR1 protein promotes the reaction [Chenodeoxycholic Acid results in increased expression of CXCL2 protein]; EGR1 protein promotes the reaction [Chenodeoxycholic Acid results in increased expression of ICAM1 mRNA]; EGR1 protein promotes the reaction [Chenodeoxycholic Acid results in increased expression of ICAM1 protein]; SL 327 inhibits the reaction [Chenodeoxycholic Acid results in increased expression of EGR1 mRNA]; SL 327 inhibits the reaction [Chenodeoxycholic Acid results in increased expression of EGR1 protein]; U 0126 inhibits the reaction [Chenodeoxycholic Acid results in increased expression of EGR1 mRNA]; U 0126 inhibits the reaction [Chenodeoxycholic Acid results in increased expression of EGR1 protein] Chenodeoxycholic Acid results in increased expression of EGR1 mRNA; Chenodeoxycholic Acid results in increased expression of EGR1 protein |
CTD |
PMID:19931294 PMID:21224055 |
|
NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of EIF2AK3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of EIF2AK3 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911
|
|
G |
Enc1 |
ectodermal-neural cortex 1 |
multiple interactions |
ISO |
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ENC1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ENC1 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 2:28,550,670...28,562,591
Ensembl chr 2:28,550,464...28,562,713
|
|
G |
Ephx1 |
epoxide hydrolase 1 |
decreases expression multiple interactions |
ISO |
Chenodeoxycholic Acid results in decreased expression of EPHX1 mRNA [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of EPHX1 mRNA |
CTD |
PMID:27174168 PMID:32152650 |
|
NCBI chr13:92,714,315...92,744,105
Ensembl chr13:92,714,315...92,790,235
|
|
G |
Fabp6 |
fatty acid binding protein 6 |
multiple interactions increases expression |
ISO |
[Chenodeoxycholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of FABP6 mRNA; Ursodeoxycholic Acid inhibits the reaction [Chenodeoxycholic Acid results in increased expression of FABP6 mRNA] |
CTD |
PMID:15821044 PMID:15935148 PMID:17963371 PMID:25582706 |
|
NCBI chr10:28,063,603...28,068,276
Ensembl chr10:28,063,603...28,068,282
|
|
G |
Fabp7 |
fatty acid binding protein 7 |
decreases expression |
ISO |
Chenodeoxycholic Acid results in decreased expression of FABP7 mRNA |
CTD |
PMID:27174168 |
|
NCBI chr20:37,123,193...37,126,725
Ensembl chr20:37,123,193...37,126,880
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions |
ISO |
Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of FASN protein]; Chenodeoxycholic Acid inhibits the reaction [tris(chloroethyl)phosphate results in increased expression of FASN protein] |
CTD |
PMID:27773935 PMID:35780845 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Fgf19 |
fibroblast growth factor 19 |
increases expression multiple interactions |
EXP ISO |
Chenodeoxycholic Acid results in increased expression of FGF15 mRNA; Chenodeoxycholic Acid results in increased expression of FGF19 protein Chenodeoxycholic Acid results in increased expression of FGF19 mRNA [[Chenodeoxycholic Acid results in increased activity of NR1H4 protein] which binds to FGF19 promoter] which results in increased expression of FGF19 mRNA; [Chenodeoxycholic Acid results in increased activity of NR1H4 protein] which binds to FGF19 promoter [Chenodeoxycholic Acid results in increased expression of FGF19 protein] which results in decreased expression of CYP7A1 protein |
CTD |
PMID:16269825 PMID:17696253 PMID:20835427 PMID:22561792 PMID:25055961 PMID:25582706 PMID:27174168 PMID:29222744 More...
|
|
NCBI chr 1:200,056,526...200,060,980
Ensembl chr 1:200,056,644...200,060,287
|
|
G |
Fkbp5 |
FKBP prolyl isomerase 5 |
multiple interactions |
ISO |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FKBP5 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr20:6,457,207...6,575,404
Ensembl chr20:6,457,216...6,541,674
|
|
G |
Fmo1 |
flavin containing dimethylaniline monoxygenase 1 |
multiple interactions |
ISO |
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FMO1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of FMO1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of FMO1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of FMO1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of FMO1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FMO1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of FMO1 mRNA |
CTD |
PMID:32152650 PMID:33819548 |
|
NCBI chr13:75,182,184...75,214,439
Ensembl chr13:75,182,176...75,214,647
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
Chenodeoxycholic Acid results in increased activity of [JUN protein co-treated with FOS protein] |
CTD |
PMID:8631127 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fosl1 |
FOS like 1, AP-1 transcription factor subunit |
multiple interactions |
ISO |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of FOSL1 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 1:202,754,549...202,763,057
Ensembl chr 1:202,754,529...202,764,930
|
|
G |
Foxm1 |
forkhead box M1 |
increases expression multiple interactions |
ISO |
Chenodeoxycholic Acid results in increased expression of FOXM1 mRNA Chenodeoxycholic Acid promotes the reaction [Carbon Tetrachloride results in increased expression of FOXM1 mRNA]; NR1H4 affects the reaction [Chenodeoxycholic Acid results in increased expression of FOXM1 mRNA] |
CTD |
PMID:22135065 PMID:25747392 |
|
NCBI chr 4:161,639,538...161,652,012
Ensembl chr 4:161,638,816...161,650,684
|
|
G |
Fth1 |
ferritin heavy chain 1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of FTH1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of FTH1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of FTH1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 1:206,627,142...206,629,430
Ensembl chr 1:206,627,103...206,725,424
|
|
G |
Ftl1 |
ferritin light chain 1 |
multiple interactions |
ISO |
[Chenodeoxycholic Acid results in increased activity of NFE2L2 protein] which results in increased expression of FTL mRNA |
CTD |
PMID:17724089 |
|
NCBI chr 1:95,936,387...95,938,234
Ensembl chr 1:95,936,387...95,939,725 Ensembl chr10:95,936,387...95,939,725 Ensembl chr 2:95,936,387...95,939,725
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions increases expression |
ISO |
[Chenodeoxycholic Acid results in increased expression of GCLC protein] which results in increased abundance of Glutathione |
CTD |
PMID:17724089 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
increases expression multiple interactions |
ISO |
Chenodeoxycholic Acid results in increased expression of GCLM protein [Chenodeoxycholic Acid results in increased expression of GCLM protein] which results in increased abundance of Glutathione; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of GCLM mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of GCLM mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of GCLM mRNA |
CTD |
PMID:17724089 PMID:33819548 |
|
NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Ggt1 |
gamma-glutamyltransferase 1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of GGT1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of GGT1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of GGT1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr20:13,074,695...13,104,095
Ensembl chr20:13,074,700...13,108,442
|
|
G |
Gjb1 |
gap junction protein, beta 1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of GJB1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of GJB1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of GJB1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of GJB1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr X:66,501,848...66,509,783
Ensembl chr X:66,501,820...66,509,925
|
|
G |
Gjb2 |
gap junction protein, beta 2 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of GJB2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of GJB2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of GJB2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of GJB2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of GJB2 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr15:31,260,390...31,278,222
Ensembl chr15:31,260,357...31,278,177
|
|
G |
Gk |
glycerol kinase |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of GK mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of GK mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of GK mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of GK mRNA |
CTD |
PMID:33819548 |
|
NCBI chr X:50,162,089...50,238,707
Ensembl chr X:50,163,123...50,238,631
|
|
G |
Got1 |
glutamic-oxaloacetic transaminase 1 |
multiple interactions |
ISO |
Chenodeoxycholic Acid inhibits the reaction [Carbon Tetrachloride results in increased secretion of GOT1 protein] |
CTD |
PMID:25747392 |
|
NCBI chr 1:242,357,293...242,381,535
Ensembl chr 1:242,357,306...242,380,633
|
|
G |
Gpbar1 |
G protein-coupled bile acid receptor 1 |
multiple interactions increases expression |
ISO |
[Chenodeoxycholic Acid binds to and results in increased activity of GPBAR1 protein] which results in increased abundance of Cyclic AMP; Chenodeoxycholic Acid binds to and results in increased activity of GPBAR1 protein Chenodeoxycholic Acid results in increased expression of GPBAR1 mRNA |
CTD |
PMID:17963371 PMID:18180267 PMID:25055961 |
|
NCBI chr 9:75,860,758...75,863,260
Ensembl chr 9:75,860,677...75,863,168
|
|
G |
Gprc5b |
G protein-coupled receptor, class C, group 5, member B |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of GPRC5B mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of GPRC5B mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of GPRC5B mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of GPRC5B mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of GPRC5B mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 1:173,316,904...173,340,933
Ensembl chr 1:173,316,907...173,340,932
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP ISO |
Chenodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in increased activity of GPT protein] Chenodeoxycholic Acid inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of GPT protein]; Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of GPT protein]; Chenodeoxycholic Acid inhibits the reaction [Carbon Tetrachloride results in increased secretion of GPT protein]; Chenodeoxycholic Acid inhibits the reaction [tris(chloroethyl)phosphate results in increased activity of GPT protein] |
CTD |
PMID:25747392 PMID:27743861 PMID:27773935 PMID:32976922 PMID:35780845 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gpx2 |
glutathione peroxidase 2 |
multiple interactions |
ISO |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GPX2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of GPX2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of GPX2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of GPX2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of GPX2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of GPX2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GPX2 mRNA |
CTD |
PMID:32152650 PMID:33819548 |
|
NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877
|
|
G |
Gsta1 |
glutathione S-transferase alpha 1 |
multiple interactions |
ISO |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of GSTA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of GSTA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of GSTA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of GSTA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTA1 mRNA |
CTD |
PMID:32152650 PMID:33819548 |
|
NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121
|
|
G |
Gsta4 |
glutathione S-transferase alpha 4 |
multiple interactions |
EXP ISO |
Chenodeoxycholic Acid binds to and results in decreased activity of GSTA4 protein [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of GSTA4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of GSTA4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of GSTA4 mRNA |
CTD |
PMID:3954743 PMID:33819548 |
|
NCBI chr 8:79,066,967...79,084,193
Ensembl chr 8:79,066,934...79,084,182
|
|
G |
Gstk1 |
glutathione S-transferase kappa 1 |
multiple interactions |
ISO |
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTK1 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 4:71,118,979...71,123,298
Ensembl chr 4:71,118,896...71,123,292
|
|
G |
Gstm1 |
glutathione S-transferase mu 1 |
multiple interactions |
EXP ISO |
Chenodeoxycholic Acid binds to and results in decreased activity of GSTM1 protein [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM1 mRNA |
CTD |
PMID:3954743 PMID:32152650 |
|
NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411
|
|
G |
Gstm2 |
glutathione S-transferase mu 2 |
multiple interactions |
EXP ISO |
Chenodeoxycholic Acid binds to and results in decreased activity of GSTM2 protein [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM2 mRNA |
CTD |
PMID:3954743 PMID:32152650 |
|
NCBI chr 2:195,624,015...195,628,774
Ensembl chr 2:195,544,426...195,628,961
|
|
G |
Gstm4 |
glutathione S-transferase mu 4 |
multiple interactions |
ISO |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of GSTM4 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 2:195,667,940...195,685,315
Ensembl chr 2:195,680,004...195,685,323
|
|
G |
Gstt1 |
glutathione S-transferase theta 1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of GSTT1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of GSTT1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of GSTT1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of GSTT1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr20:12,856,613...12,873,586
Ensembl chr20:12,856,669...12,873,585
|
|
G |
Hacl1 |
2-hydroxyacyl-CoA lyase 1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of HACL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of HACL1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr16:6,826,881...6,863,027
Ensembl chr16:6,824,906...6,863,027
|
|
G |
Herpud1 |
homocysteine inducible ER protein with ubiquitin like domain 1 |
multiple interactions |
ISO |
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HERPUD1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HERPUD1 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr19:10,598,411...10,609,002
Ensembl chr19:10,598,417...10,618,424
|
|
G |
Hgf |
hepatocyte growth factor |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of HGF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of HGF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of HGF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of HGF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of HGF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of HGF mRNA; Chenodeoxycholic Acid inhibits the reaction [Cholera Toxin results in increased expression of HGF protein] |
CTD |
PMID:15802798 PMID:33819548 |
|
NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409
|
|
G |
Hhex |
hematopoietically expressed homeobox |
multiple interactions increases expression |
ISO |
Chenodeoxycholic Acid promotes the reaction [NR1H4 binds to HHEX intron]; NR1H4 affects the reaction [Chenodeoxycholic Acid results in increased expression of HHEX mRNA] NR1H4 mutant form inhibits the reaction [Chenodeoxycholic Acid results in increased expression of HHEX mRNA]; NR1H4 mutant form inhibits the reaction [Chenodeoxycholic Acid results in increased expression of HHEX protein] Chenodeoxycholic Acid results in increased expression of HHEX mRNA; Chenodeoxycholic Acid results in increased expression of HHEX protein |
CTD |
PMID:19072826 |
|
NCBI chr 1:235,190,455...235,196,042
Ensembl chr 1:235,190,455...235,196,042
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions |
ISO |
HIF1A mutant form inhibits the reaction [Chenodeoxycholic Acid results in increased expression of SLC51A mRNA] |
CTD |
PMID:24703425 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
decreases response to substance multiple interactions decreases activity |
ISO EXP |
HMGCR protein results in decreased susceptibility to Chenodeoxycholic Acid [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of HMGCR mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of HMGCR mRNA Chenodeoxycholic Acid results in decreased activity of HMGCR protein |
CTD |
PMID:6832710 PMID:7461467 PMID:33819548 |
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Hmgcs1 |
3-hydroxy-3-methylglutaryl-CoA synthase 1 |
affects expression |
ISO |
Chenodeoxycholic Acid affects the expression of HMGCS1 mRNA |
CTD |
PMID:31437187 |
|
NCBI chr 2:51,649,368...51,667,100
Ensembl chr 2:51,649,497...51,667,100
|
|
G |
Hmgcs2 |
3-hydroxy-3-methylglutaryl-CoA synthase 2 |
decreases expression |
ISO |
Chenodeoxycholic Acid results in decreased expression of HMGCS2 mRNA |
CTD |
PMID:27174168 |
|
NCBI chr 2:185,875,609...185,903,505
Ensembl chr 2:185,875,616...185,902,130
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
ISO |
[Chenodeoxycholic Acid results in increased activity of NFE2L2 protein] which results in increased expression of HMOX1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HMOX1 mRNA |
CTD |
PMID:17724089 PMID:32152650 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hpx |
hemopexin |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of HPX mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of HPX mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of HPX mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of HPX mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of HPX mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of HPX mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of HPX mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 1:159,932,819...159,940,327
Ensembl chr 1:159,932,755...159,940,328
|
|
G |
Hsd11b1 |
hydroxysteroid 11-beta dehydrogenase 1 |
decreases activity increases abundance multiple interactions |
ISO |
Chenodeoxycholic Acid results in decreased activity of HSD11B1 protein HSD11B1 gene mutant form results in increased abundance of Chenodeoxycholic Acid [HSD11B1 protein results in increased reduction of 7-ketolithocholic acid] which results in increased chemical synthesis of Chenodeoxycholic Acid |
CTD |
PMID:10664531 PMID:21453287 PMID:25061560 |
|
NCBI chr13:104,728,539...104,798,884
Ensembl chr13:104,728,539...104,788,687
|
|
G |
Hsd3b7 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 7 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of HSD3B7 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of HSD3B7 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of HSD3B7 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 1:182,412,216...182,415,447
Ensembl chr 1:182,412,151...182,415,442
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
ISO |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of HSPA5 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HSPA5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of HSPA5 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HSPA5 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Hspb8 |
heat shock protein family B (small) member 8 |
multiple interactions |
ISO |
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of HSPB8 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr12:40,176,405...40,205,002
Ensembl chr12:40,176,532...40,191,185
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
increases expression multiple interactions |
ISO |
Chenodeoxycholic Acid results in increased expression of ICAM1 mRNA; Chenodeoxycholic Acid results in increased expression of ICAM1 protein BAY 11-7085 inhibits the reaction [Chenodeoxycholic Acid results in increased expression of ICAM1 mRNA]; SB 203580 inhibits the reaction [Chenodeoxycholic Acid results in increased expression of ICAM1 mRNA] EGR1 protein promotes the reaction [Chenodeoxycholic Acid results in increased expression of ICAM1 mRNA]; EGR1 protein promotes the reaction [Chenodeoxycholic Acid results in increased expression of ICAM1 protein] |
CTD |
PMID:16582018 PMID:21224055 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Ier3 |
immediate early response 3 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of IER3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of IER3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of IER3 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr20:2,928,378...2,929,582
Ensembl chr20:2,928,378...2,929,583
|
|
G |
Ifi27 |
interferon, alpha-inducible protein 27 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of IFI27 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of IFI27 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of IFI27 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of IFI27 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of IFI27 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of IFI27 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 6:122,590,461...122,596,996
Ensembl chr 6:122,590,472...122,779,294
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
EXP |
Chenodeoxycholic Acid inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide] |
CTD |
PMID:12620498 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Igfbp1 |
insulin-like growth factor binding protein 1 |
decreases expression multiple interactions |
ISO |
Chenodeoxycholic Acid results in decreased expression of IGFBP1 mRNA [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of IGFBP1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of IGFBP1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of IGFBP1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of IGFBP1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of IGFBP1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of IGFBP1 mRNA |
CTD |
PMID:19072826 PMID:33819548 |
|
NCBI chr14:82,047,415...82,052,482
Ensembl chr14:82,047,415...82,052,482
|
|
G |
Il10 |
interleukin 10 |
decreases abundance |
ISO |
IL10 gene mutant form results in decreased abundance of Chenodeoxycholic Acid |
CTD |
PMID:27580383 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
Chenodeoxycholic Acid affects the reaction [alisol A 24-acetate inhibits the reaction [[Choline deficiency co-treated with Methionine deficiency] results in increased expression of IL1B mRNA]] |
CTD |
PMID:29883724 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il1r1 |
interleukin 1 receptor type 1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of IL1R1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of IL1R1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of IL1R1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of IL1R1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 9:42,504,917...42,580,958
Ensembl chr 9:42,504,735...42,579,937
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of IL6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of IL6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of IL6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of IL6 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of JUN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of JUN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of JUN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of JUN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of JUN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUN mRNA; Chenodeoxycholic Acid results in increased activity of [JUN protein co-treated with FOS protein] |
CTD |
PMID:8631127 PMID:32152650 PMID:33819548 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Jund |
JunD proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of JUND mRNA |
CTD |
PMID:32152650 |
|
NCBI chr16:18,734,121...18,735,799
Ensembl chr16:18,734,122...18,735,799
|
|
G |
Kynu |
kynureninase |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of KYNU mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of KYNU mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of KYNU mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of KYNU mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 3:27,778,646...27,929,470
Ensembl chr 3:27,778,772...27,929,488
|
|
G |
Lbp |
lipopolysaccharide binding protein |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of LBP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of LBP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of LBP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of LBP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of LBP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of LBP mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 3:146,953,889...146,981,032
Ensembl chr 3:146,954,015...146,981,586
|
|
G |
Ldlr |
low density lipoprotein receptor |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of LDLR mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of LDLR mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of LDLR mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of LDLR mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580
|
|
G |
Lipc |
lipase C, hepatic type |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of LIPC mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of LIPC mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of LIPC mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of LIPC mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of LIPC mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of LIPC mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 8:71,509,633...71,635,663
Ensembl chr 8:71,509,635...71,635,464
|
|
G |
Lpl |
lipoprotein lipase |
multiple interactions |
ISO |
Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in decreased expression of LPL mRNA]; Chenodeoxycholic Acid inhibits the reaction [tris(chloroethyl)phosphate results in increased expression of LPL mRNA] |
CTD |
PMID:27773935 PMID:35780845 |
|
NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
|
|
G |
Lrp2 |
LDL receptor related protein 2 |
increases expression multiple interactions |
ISO |
Chenodeoxycholic Acid results in increased expression of LRP2 protein NR1H4 protein promotes the reaction [Chenodeoxycholic Acid results in increased expression of LRP2 protein] |
CTD |
PMID:15375181 |
|
NCBI chr 3:54,189,305...54,346,769
Ensembl chr 3:54,189,308...54,346,708
|
|
G |
Ly96 |
lymphocyte antigen 96 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of LY96 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of LY96 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of LY96 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of LY96 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of LY96 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 5:2,582,233...2,612,357
Ensembl chr 5:2,582,254...2,612,386
|
|
G |
Maf |
MAF bZIP transcription factor |
multiple interactions |
ISO |
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of MAF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of MAF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of MAF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of MAF mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAF mRNA |
CTD |
PMID:32152650 PMID:33819548 |
|
NCBI chr19:43,353,867...43,713,162
Ensembl chr19:43,360,342...43,712,365
|
|
G |
Maff |
MAF bZIP transcription factor F |
multiple interactions |
ISO |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of MAFF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of MAFF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MAFF mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAFF mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFF mRNA |
CTD |
PMID:32152650 PMID:33819548 |
|
NCBI chr 7:110,912,367...110,923,711
Ensembl chr 7:110,912,499...110,923,851
|
|
G |
Mafg |
MAF bZIP transcription factor G |
multiple interactions |
ISO |
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFG mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFG mRNA |
CTD |
PMID:32152650 |
|
NCBI chr10:105,903,307...105,911,808
Ensembl chr10:105,903,237...105,912,026
|
|
G |
Mafk |
MAF bZIP transcription factor K |
multiple interactions |
ISO |
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFK mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAFK mRNA |
CTD |
PMID:32152650 |
|
NCBI chr12:14,834,628...14,856,414
Ensembl chr12:14,833,984...14,837,048 Ensembl chr12:14,833,984...14,837,048
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
increases expression multiple interactions |
ISO |
Chenodeoxycholic Acid results in increased expression of MAP1LC3B protein [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP1LC3B mRNA |
CTD |
PMID:24189133 PMID:32152650 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690 Ensembl chr16:49,665,791...49,677,690
|
|
G |
Map2k1 |
mitogen activated protein kinase kinase 1 |
multiple interactions |
ISO |
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP2K1 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 8:64,683,449...64,754,900
Ensembl chr 8:64,683,449...64,755,147
|
|
G |
Map2k2 |
mitogen activated protein kinase kinase 2 |
multiple interactions |
ISO |
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAP2K2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of MAP2K2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MAP2K2 mRNA |
CTD |
PMID:32152650 PMID:33819548 |
|
NCBI chr 7:8,590,729...8,610,279
Ensembl chr 7:8,580,905...8,610,243
|
|
G |
Map2k6 |
mitogen-activated protein kinase kinase 6 |
multiple interactions |
ISO |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of MAP2K6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of MAP2K6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of MAP2K6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of MAP2K6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA |
CTD |
PMID:32152650 PMID:33819548 |
|
NCBI chr10:95,373,304...95,490,406
Ensembl chr10:95,373,204...95,488,293
|
|
G |
Map3k5 |
mitogen-activated protein kinase kinase kinase 5 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of MAP3K5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MAP3K5 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 1:14,685,776...14,904,935
Ensembl chr 1:14,685,492...14,904,800
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation multiple interactions |
ISO |
Chenodeoxycholic Acid results in increased phosphorylation of MAPK1 protein Chenodeoxycholic Acid inhibits the reaction [1-Naphthylisothiocyanate results in increased phosphorylation of MAPK1 protein]; SL 327 inhibits the reaction [Chenodeoxycholic Acid results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [Chenodeoxycholic Acid results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:19931294 PMID:32976922 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
ISO |
Chenodeoxycholic Acid inhibits the reaction [1-Naphthylisothiocyanate results in increased phosphorylation of MAPK3 protein]; SL 327 inhibits the reaction [Chenodeoxycholic Acid results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [Chenodeoxycholic Acid results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:19931294 PMID:32976922 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
ISO |
Chenodeoxycholic Acid inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK8 protein]; Chenodeoxycholic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:25496033 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
multiple interactions |
ISO |
Chenodeoxycholic Acid inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK9 protein]; Chenodeoxycholic Acid inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of MAPK9 protein] [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPK9 mRNA |
CTD |
PMID:25496033 PMID:32152650 |
|
NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178
|
|
G |
Mapkapk3 |
MAPK activated protein kinase 3 |
multiple interactions |
ISO |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of MAPKAPK3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MAPKAPK3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MAPKAPK3 mRNA |
CTD |
PMID:32152650 PMID:33819548 |
|
NCBI chr 8:107,929,754...107,963,638
Ensembl chr 8:107,929,762...107,963,568
|
|
G |
Mgst1 |
microsomal glutathione S-transferase 1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of MGST1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of MGST1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MGST1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 4:171,029,666...171,044,893
Ensembl chr 4:171,029,630...171,044,892
|
|
G |
Mgst2 |
microsomal glutathione S-transferase 2 |
multiple interactions |
ISO |
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MGST2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of MGST2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of MGST2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of MGST2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MGST2 mRNA |
CTD |
PMID:32152650 PMID:33819548 |
|
NCBI chr 2:135,679,524...135,715,828
Ensembl chr 2:135,693,557...135,715,828
|
|
G |
Mir15b |
microRNA 15b |
increases expression |
ISO |
Chenodeoxycholic Acid results in increased expression of MIR15B mRNA |
CTD |
PMID:27174168 |
|
NCBI chr 2:153,245,200...153,245,297
Ensembl chr 2:153,245,200...153,245,297
|
|
G |
Mir190 |
microRNA 190 |
decreases expression |
ISO |
Chenodeoxycholic Acid results in decreased expression of MIR190A mRNA |
CTD |
PMID:27174168 |
|
NCBI chr 8:67,850,987...67,851,071
Ensembl chr 8:67,850,987...67,851,071
|
|
G |
Mir190b |
microRNA 190b |
decreases expression |
ISO |
Chenodeoxycholic Acid results in decreased expression of MIR190B mRNA |
CTD |
PMID:27174168 |
|
NCBI chr 2:175,514,800...175,514,877
Ensembl chr 2:175,514,800...175,514,877
|
|
G |
Mir204 |
microRNA 204 |
increases expression |
ISO |
Chenodeoxycholic Acid results in increased expression of MIR204 mRNA |
CTD |
PMID:27174168 |
|
NCBI chr 1:220,316,931...220,317,040
Ensembl chr 1:220,316,931...220,317,040
|
|
G |
Mir30a |
microRNA 30a |
decreases expression |
ISO |
Chenodeoxycholic Acid results in decreased expression of MIR30A mRNA |
CTD |
PMID:27174168 |
|
NCBI chr 9:25,737,600...25,737,670
Ensembl chr 9:25,737,600...25,737,670
|
|
G |
Mir328 |
microRNA 328 |
increases expression |
ISO |
Chenodeoxycholic Acid results in increased expression of MIR328 mRNA |
CTD |
PMID:27174168 |
|
NCBI chr19:33,184,766...33,184,849
Ensembl chr19:33,184,766...33,184,849
|
|
G |
Mir34a |
microRNA 34a |
decreases expression |
ISO |
Chenodeoxycholic Acid results in decreased expression of MIR34A mRNA |
CTD |
PMID:27174168 |
|
NCBI chr 5:160,533,002...160,533,103
Ensembl chr 5:160,533,002...160,533,103
|
|
G |
Mir451a |
microRNA 451a |
decreases expression |
ISO |
Chenodeoxycholic Acid results in decreased expression of MIR451A mRNA |
CTD |
PMID:27174168 |
|
NCBI chr10:62,961,520...62,961,591
Ensembl chr10:62,961,520...62,961,591
|
|
G |
Mir486 |
microRNA 486 |
decreases expression |
ISO |
Chenodeoxycholic Acid results in decreased expression of MIR486-1 mRNA |
CTD |
PMID:27174168 |
|
|
|
G |
Mir92a2 |
microRNA 92a-2 |
increases expression |
ISO |
Chenodeoxycholic Acid results in increased expression of MIR92A2 mRNA |
CTD |
PMID:27174168 |
|
NCBI chr X:132,421,942...132,422,033
Ensembl chr X:132,421,942...132,422,033
|
|
G |
Mir98 |
microRNA 98 |
decreases expression |
ISO |
Chenodeoxycholic Acid results in decreased expression of MIR98 mRNA |
CTD |
PMID:27174168 |
|
NCBI chr X:20,981,235...20,981,342
Ensembl chr X:20,981,235...20,981,342
|
|
G |
Mlkl |
mixed lineage kinase domain like pseudokinase |
multiple interactions |
ISO |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of MLKL mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of MLKL mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of MLKL mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of MLKL mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of MLKL mRNA |
CTD |
PMID:32152650 PMID:33819548 |
|
NCBI chr19:39,277,526...39,304,555
Ensembl chr19:39,276,785...39,304,502
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions |
ISO |
Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of MMP2 mRNA] |
CTD |
PMID:27773935 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmut |
methylmalonyl-CoA mutase |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of MMUT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of MMUT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of MMUT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of MMUT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of MMUT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MMUT mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 9:19,928,720...19,956,985
Ensembl chr 9:19,928,727...19,957,046
|
|
G |
Mttp |
microsomal triglyceride transfer protein |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of MTTP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of MTTP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of MTTP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of MTTP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of MTTP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of MTTP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MTTP mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 2:226,613,090...226,654,239
Ensembl chr 2:226,613,090...226,654,239
|
|
G |
Ncoa1 |
nuclear receptor coactivator 1 |
multiple interactions |
ISO |
Chenodeoxycholic Acid analog promotes the reaction [NR1H4 protein binds to NCOA1 protein]; Chenodeoxycholic Acid promotes the reaction [NR1H4 protein binds to NCOA1 protein]; Ketoconazole inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein binds to NCOA1 protein]] |
CTD |
PMID:13130122 PMID:14684751 PMID:16819505 |
|
NCBI chr 6:27,232,609...27,507,992
Ensembl chr 6:27,232,611...27,475,664
|
|
G |
Ncoa2 |
nuclear receptor coactivator 2 |
multiple interactions |
ISO |
22,23-dihydroavermectin B(1)a inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein affects the localization of NCOA2 protein]]; benidipine inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]; Chenodeoxycholic Acid promotes the reaction [NR1H4 protein affects the localization of NCOA2 protein]; cilnidipine inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; clevidipine inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Colchicine inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein affects the localization of NCOA2 protein]]; Daunorubicin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein affects the localization of NCOA2 protein]]; doramectin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Doxorubicin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Doxorubicin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein affects the localization of NCOA2 protein]]; emamectin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Epirubicin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein affects the localization of NCOA2 protein]]; eprinomectin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Felodipine inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Isradipine inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Ivermectin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; lacidipine inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; moxidectin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Nicardipine inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Nimodipine inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; pregna-4,17-diene-3,16-dione inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; selamectin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]] |
CTD |
PMID:25257666 PMID:27773686 |
|
NCBI chr 5:5,835,642...6,069,693
Ensembl chr 5:5,835,706...6,067,451
|
|
G |
Ncor1 |
nuclear receptor co-repressor 1 |
multiple interactions |
ISO |
7-hydroxytheonellasterol inhibits the reaction [Chenodeoxycholic Acid inhibits the reaction [NCOR1 protein binds to SLC51A promoter]]; Chenodeoxycholic Acid inhibits the reaction [NCOR1 protein binds to SLC51A promoter] |
CTD |
PMID:22291955 |
|
NCBI chr10:46,999,536...47,142,294
Ensembl chr10:46,999,536...47,141,032
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions increases expression decreases response to substance |
ISO |
[Chenodeoxycholic Acid results in increased activity of NFE2L2 protein] which results in increased expression of FTL mRNA; [Chenodeoxycholic Acid results in increased activity of NFE2L2 protein] which results in increased expression of HMOX1 mRNA; [Chenodeoxycholic Acid results in increased activity of NFE2L2 protein] which results in increased expression of NQO1 mRNA; [Chenodeoxycholic Acid results in increased activity of NFE2L2 protein] which results in increased expression of TXN mRNA; Chenodeoxycholic Acid results in increased expression of and results in increased localization of and results in increased activity of NFE2L2 protein Chenodeoxycholic Acid results in increased expression of NFE2L2 mRNA NFE2L2 protein results in decreased susceptibility to Chenodeoxycholic Acid |
CTD |
PMID:17724089 PMID:25582706 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfxl1 |
nuclear transcription factor, X-box binding-like 1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of NFXL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of NFXL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of NFXL1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr14:35,626,086...35,667,505
Ensembl chr14:35,626,066...35,667,498
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions increases expression |
ISO |
[Chenodeoxycholic Acid results in increased activity of NFE2L2 protein] which results in increased expression of NQO1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NQO1 mRNA Chenodeoxycholic Acid results in increased expression of NQO1 mRNA |
CTD |
PMID:17724089 PMID:25582706 PMID:32152650 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nqo2 |
N-ribosyldihydronicotinamide:quinone dehydrogenase 2 |
multiple interactions |
ISO |
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of NQO2 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr17:30,909,482...30,938,725
Ensembl chr17:30,909,187...30,938,320
|
|
G |
Nr0b2 |
nuclear receptor subfamily 0, group B, member 2 |
multiple interactions increases expression |
ISO EXP |
7-hydroxytheonellasterol inhibits the reaction [Chenodeoxycholic Acid results in increased expression of NR0B2 mRNA]; [Chenodeoxycholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of NR0B2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of NR0B2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of NR0B2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of NR0B2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of NR0B2 mRNA; epigallocatechin gallate inhibits the reaction [Chenodeoxycholic Acid results in increased expression of NR0B2 mRNA]; NR1H4 affects the reaction [Chenodeoxycholic Acid results in increased expression of NR0B2 mRNA] Chenodeoxycholic Acid inhibits the reaction [tris(chloroethyl)phosphate results in decreased expression of NR0B2 protein]; Chenodeoxycholic Acid promotes the reaction [Carbon Tetrachloride results in decreased expression of NR0B2 mRNA]; NR1H4 protein promotes the reaction [Chenodeoxycholic Acid results in increased expression of NR0B2 mRNA] [Chenodeoxycholic Acid binds to NR1H4 protein] which results in increased expression of NR0B2 mRNA |
CTD |
PMID:15980055 PMID:16037943 PMID:16269825 PMID:16357303 PMID:16946559 PMID:17963371 PMID:19072826 PMID:19562681 PMID:22178739 PMID:22291955 PMID:22540009 PMID:24189133 PMID:25055961 PMID:25582706 PMID:25747392 PMID:27174168 PMID:27743861 PMID:29222744 PMID:33819548 PMID:35780845 More...
|
|
NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609
|
|
G |
Nr1d1 |
nuclear receptor subfamily 1, group D, member 1 |
affects expression |
ISO |
Chenodeoxycholic Acid affects the expression of NR1D1 mRNA |
CTD |
PMID:31437187 |
|
NCBI chr10:83,728,348...83,735,562
Ensembl chr10:83,728,318...83,735,705
|
|
G |
Nr1d2 |
nuclear receptor subfamily 1, group D, member 2 |
increases expression affects expression |
ISO |
Chenodeoxycholic Acid results in increased expression of NR1D2 mRNA Chenodeoxycholic Acid affects the expression of NR1D2 mRNA |
CTD |
PMID:19072826 PMID:31437187 |
|
NCBI chr15:7,524,257...7,550,553
Ensembl chr15:7,524,257...7,550,553
|
|
G |
Nr1h2 |
nuclear receptor subfamily 1, group H, member 2 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of NR1H2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of NR1H2 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 1:95,041,967...95,047,358
Ensembl chr 1:95,041,967...95,047,377
|
|
G |
Nr1h3 |
nuclear receptor subfamily 1, group H, member 3 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of NR1H3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of NR1H3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of NR1H3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of NR1H3 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
multiple interactions increases expression increases activity affects binding affects activity increases response to substance |
ISO EXP |
Chenodeoxycholic Acid binds to and results in increased activity of NR1H4 protein; Chenodeoxycholic Acid inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of NR1H4 mRNA]; Chenodeoxycholic Acid inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of NR1H4 protein]; Chenodeoxycholic Acid inhibits the reaction [tris(chloroethyl)phosphate results in decreased expression of NR1H4 mRNA]; Chenodeoxycholic Acid inhibits the reaction [tris(chloroethyl)phosphate results in decreased expression of NR1H4 protein]; epiallopregnanolone sulfate inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; NR1H4 affects the reaction [Chenodeoxycholic Acid results in increased expression of FOXM1 mRNA]; NR1H4 mutant form inhibits the reaction [Chenodeoxycholic Acid results in decreased expression of CYP7A1 mRNA]; NR1H4 mutant form inhibits the reaction [Chenodeoxycholic Acid results in increased expression of HHEX mRNA]; NR1H4 mutant form inhibits the reaction [Chenodeoxycholic Acid results in increased expression of HHEX protein]; NR1H4 protein promotes the reaction [Chenodeoxycholic Acid results in decreased expression of CYP17A1 mRNA]; NR1H4 protein promotes the reaction [Chenodeoxycholic Acid results in decreased expression of SULT2A1 mRNA]; NR1H4 protein promotes the reaction [Chenodeoxycholic Acid results in increased expression of ABCB11 mRNA]; NR1H4 protein promotes the reaction [Chenodeoxycholic Acid results in increased expression of LRP2 protein]; NR1H4 protein promotes the reaction [Chenodeoxycholic Acid results in increased expression of NR0B2 mRNA]; Pregnanolone metabolite inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein] chenodeoxycholic acid enhances the reaction [glycyrrhetinic acid increases expression of Nr1h4 mRNA in liver] chenodeoxycholic acid increases expression of Nr1H4 mRNA in rat hepatic stellate cells chenodeoxycholic acid inhibits the reaction [Carbon Tetrachloride decreases expression of Nr1h4 mRNA in rat liver], increases expression of Nr1H4 mRNA in rat liver Chenodeoxycholic Acid metabolite results in increased activity of NR1H4 protein; Chenodeoxycholic Acid results in increased activity of NR1H4 protein Chenodeoxycholic Acid results in increased expression of NR1H4 mRNA; Chenodeoxycholic Acid results in increased expression of NR1H4 protein [Chenodeoxycholic Acid binds to NR1H4 protein] which results in increased expression of NR0B2 mRNA; [Chenodeoxycholic Acid binds to NR1H4 protein] which results in increased expression of SLC51A mRNA; [Chenodeoxycholic Acid binds to NR1H4 protein] which results in increased expression of SLC51B mRNA; Chenodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in decreased expression of NR1H4 mRNA]; Chenodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in decreased expression of NR1H4 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Chenodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in decreased expression of NR1H4 mRNA]] 1,4-dihydropyridine inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; 22,23-dihydroavermectin B(1)a inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein affects the localization of NCOA2 protein]]; 22,23-dihydroavermectin B(1)a inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; 4,4'-hexafluorisopropylidene diphenol inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; 7-hydroxytheonellasterol inhibits the reaction [[Chenodeoxycholic Acid promotes the reaction [NR1H4 protein binds to ABCC4 promoter]] which results in decreased expression of ABCC4 mRNA]; 7-hydroxytheonellasterol inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein binds to ABCC4 promoter]]; 7-hydroxytheonellasterol inhibits the reaction [Chenodeoxycholic Acid results in increased expression of NR1H4 mRNA]; [[Chenodeoxycholic Acid binds to and results in increased activity of NR1H4 protein] which binds to ABCB4 promoter] which results in increased expression of ABCB4 mRNA; [[Chenodeoxycholic Acid results in increased activity of NR1H4 protein] which binds to FGF19 promoter] which results in increased expression of FGF19 mRNA; [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1H4 mRNA; [Chenodeoxycholic Acid analog binds to and results in increased activity of NR1H4 protein] which results in decreased expression of CYP7A1 mRNA; [Chenodeoxycholic Acid binds to and results in increased activity of NR1H4 protein] which results in decreased expression of CYP7A1 mRNA; [Chenodeoxycholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of ABCB11 mRNA; [Chenodeoxycholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of FABP6 mRNA; [Chenodeoxycholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of NR0B2 mRNA; [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein binds to ABCC4 promoter]] which results in decreased expression of ABCC4 mRNA; [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein binds to UGT1A3 promoter]] which results in increased expression of UGT1A3 mRNA; [Chenodeoxycholic Acid results in increased activity of NR1H4 protein] which binds to FGF19 promoter; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1H4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of NR1H4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of NR1H4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of NR1H4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1H4 mRNA; abamectin inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; alpha-Linolenic Acid inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Am 580 inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Aminacrine inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Arachidonic Acid inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; benazepril inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; benidipine inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Chenodeoxycholic Acid analog binds to and results in increased activity of NR1H4 protein; Chenodeoxycholic Acid analog promotes the reaction [NR1H4 protein binds to NCOA1 protein]; Chenodeoxycholic Acid binds to and results in increased activity of NR1H4 protein; Chenodeoxycholic Acid inhibits the reaction [cholyl-lysylfluorescein binds to NR1H4 protein modified form]; Chenodeoxycholic Acid inhibits the reaction [Ursodeoxycholic Acid binds to NR1H4 protein]; Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]; Chenodeoxycholic Acid promotes the reaction [NR1H4 binds to HHEX intron]; Chenodeoxycholic Acid promotes the reaction [NR1H4 protein affects the localization of NCOA2 protein]; Chenodeoxycholic Acid promotes the reaction [NR1H4 protein binds to ABCC4 promoter]; Chenodeoxycholic Acid promotes the reaction [NR1H4 protein binds to NCOA1 protein]; Chenodeoxycholic Acid promotes the reaction [NR1H4 protein binds to UGT1A3 promoter]; cilnidipine inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; cilnidipine inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; clevidipine inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Colchicine inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein affects the localization of NCOA2 protein]]; cyclopamine inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Daunorubicin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein affects the localization of NCOA2 protein]]; Daunorubicin inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Decitabine inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Deoxycholic Acid inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Docosahexaenoic Acids inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; doramectin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; doramectin inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Doxorubicin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Doxorubicin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein affects the localization of NCOA2 protein]]; Doxorubicin inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; emamectin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; emamectin inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; epigallocatechin gallate inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; epigallocatechin gallate inhibits the reaction [Chenodeoxycholic Acid results in increased expression of NR1H4 mRNA]; Epirubicin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein affects the localization of NCOA2 protein]]; Epirubicin inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; eprinomectin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Ethacridine inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Felodipine inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Felodipine inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; fluoxastrobin inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; GW 4064 inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Isotretinoin inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Isradipine inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Ivermectin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Ketoconazole inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NR1H4 protein binds to NCOA1 protein]]; Ketoconazole inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; lacidipine inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; lacidipine inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Lithocholic Acid inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; manidipine inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Mitomycin inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; moxidectin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; moxidectin inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Nicardipine inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Nicardipine inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Nimodipine inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Nitrendipine inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; NR1H4 affects the reaction [Chenodeoxycholic Acid results in increased expression of HHEX mRNA]; NR1H4 affects the reaction [Chenodeoxycholic Acid results in increased expression of NR0B2 mRNA]; NR1H4 mutant form inhibits the reaction [Chenodeoxycholic Acid results in increased expression of SLC51A mRNA]; NR1H4 mutant form inhibits the reaction [Chenodeoxycholic Acid results in increased expression of SLC51B mRNA]; NR1H4 protein affects the reaction [Chenodeoxycholic Acid results in increased expression of SLC51A mRNA]; NR1H4 protein affects the reaction [Chenodeoxycholic Acid results in increased expression of SLC51B mRNA]; picoxystrobin inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; pirarubicin inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; pregna-4,17-diene-3,16-dione inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; Proflavine inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Rotenone inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; selamectin inhibits the reaction [Chenodeoxycholic Acid promotes the reaction [NCOA2 protein modified form binds to NR1H4 protein]]; selamectin inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; ST 1481 inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; tamibarotene inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Topotecan inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; Tretinoin inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; trifloxystrobin inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein]; UGT1A3 protein affects the reaction [Chenodeoxycholic Acid affects the activity of NR1H4 protein]; Ursodeoxycholic Acid inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein] NR1H4 results in increased susceptibility to Chenodeoxycholic Acid |
CTD RGD |
PMID:12519787 PMID:12525500 PMID:13130122 PMID:14527955 PMID:14684751 PMID:15145977 PMID:15307955 PMID:15375181 PMID:15489543 PMID:15576845 PMID:15935148 PMID:15980055 PMID:16037943 PMID:16357303 PMID:16423920 PMID:16819505 PMID:16946559 PMID:17058234 PMID:17567710 PMID:17963371 PMID:18180267 PMID:19072826 PMID:19445040 PMID:19562681 PMID:20189675 PMID:21291553 PMID:22135065 PMID:22178739 PMID:22291955 PMID:22414727 PMID:22561792 PMID:22961653 PMID:24703425 PMID:25055961 PMID:25257666 PMID:25278094 PMID:27743861 PMID:27773686 PMID:27871908 PMID:30408883 PMID:30818834 PMID:32152650 PMID:32976922 PMID:33819548 PMID:35780845 PMID:36709907 PMID:30061734 PMID:15980055 PMID:19418582 More...
|
RGD:15092071, RGD:1625201, RGD:15042868 |
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
multiple interactions increases activity |
ISO |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I2 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of NR1I2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of NR1I2 mRNA; Chenodeoxycholic Acid analog binds to and results in increased activity of NR1I2 protein; Chenodeoxycholic Acid binds to and results in increased activity of NR1I2 protein Chenodeoxycholic Acid metabolite results in increased activity of NR1I2 protein |
CTD |
PMID:17963371 PMID:27871908 PMID:32152650 PMID:33819548 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
increases expression multiple interactions decreases expression |
ISO |
Chenodeoxycholic Acid results in increased expression of NR1I3 mRNA [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of NR1I3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of NR1I3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of NR1I3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of NR1I3 mRNA Chenodeoxycholic Acid results in decreased expression of NR1I3 mRNA |
CTD |
PMID:16929008 PMID:27174168 PMID:32152650 PMID:33819548 |
|
NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Pah |
phenylalanine hydroxylase |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of PAH mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of PAH mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of PAH mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of PAH mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of PAH mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of PAH mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PAH mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 7:21,933,179...21,998,134
Ensembl chr 7:21,933,179...21,998,130
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions increases cleavage |
ISO |
[Chenodeoxycholic Acid co-treated with ursodoxicoltaurine] results in increased cleavage of PARP1 protein Chenodeoxycholic Acid results in increased cleavage of PARP1 protein |
CTD |
PMID:14976352 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pex3 |
peroxisomal biogenesis factor 3 |
decreases expression |
ISO |
Chenodeoxycholic Acid results in decreased expression of PEX3 mRNA |
CTD |
PMID:27174168 |
|
NCBI chr 1:7,912,508...7,954,474
Ensembl chr 1:7,912,506...7,954,518
|
|
G |
Pik3c2a |
phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 alpha |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of PIK3C2A mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of PIK3C2A mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of PIK3C2A mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of PIK3C2A mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of PIK3C2A mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 1:170,577,942...170,684,353
Ensembl chr 1:170,577,942...170,683,472
|
|
G |
Pik3c2b |
phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 beta |
multiple interactions |
ISO |
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2B mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2B mRNA |
CTD |
PMID:32152650 |
|
NCBI chr13:44,494,673...44,555,663
Ensembl chr13:44,495,050...44,555,612
|
|
G |
Pik3c2g |
phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 gamma |
multiple interactions |
ISO |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of PIK3C2G mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of PIK3C2G mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of PIK3C2G mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C2G mRNA |
CTD |
PMID:32152650 PMID:33819548 |
|
NCBI chr 4:172,483,752...172,851,623
Ensembl chr 4:172,484,345...172,850,544
|
|
G |
Pik3c3 |
phosphatidylinositol 3-kinase, catalytic subunit type 3 |
multiple interactions |
ISO |
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3C3 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr18:21,845,282...21,934,387
Ensembl chr18:21,845,295...21,929,048
|
|
G |
Pik3r1 |
phosphoinositide-3-kinase regulatory subunit 1 |
multiple interactions |
ISO |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3R1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3R1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of PIK3R1 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 2:32,878,942...32,963,668
Ensembl chr 2:32,882,032...32,963,631
|
|
G |
Pik3r3 |
phosphoinositide-3-kinase regulatory subunit 3 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of PIK3R3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of PIK3R3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of PIK3R3 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 5:129,700,925...129,772,591
Ensembl chr 5:129,701,229...129,772,583
|
|
G |
Plaur |
plasminogen activator, urokinase receptor |
increases expression |
ISO |
Chenodeoxycholic Acid results in increased expression of PLAUR mRNA |
CTD |
PMID:21224055 |
|
NCBI chr 1:80,053,440...80,068,384
Ensembl chr 1:80,050,324...80,068,595
|
|
G |
Pon1 |
paraoxonase 1 |
multiple interactions decreases expression |
ISO |
pyrazolanthrone inhibits the reaction [Chenodeoxycholic Acid results in decreased expression of PON1 mRNA] |
CTD |
PMID:16269825 |
|
NCBI chr 4:33,294,737...33,325,759
Ensembl chr 4:33,294,722...33,321,360
|
|
G |
Por |
cytochrome p450 oxidoreductase |
increases abundance |
ISO |
POR gene mutant form results in increased abundance of Chenodeoxycholic Acid |
CTD |
PMID:25034404 |
|
NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
increases expression multiple interactions |
EXP ISO |
Chenodeoxycholic Acid results in increased expression of PPARA mRNA [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of PPARA mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of PPARA mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of PPARA mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of PPARA mRNA Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in decreased expression of PPARA mRNA]; Chenodeoxycholic Acid inhibits the reaction [tris(chloroethyl)phosphate results in decreased expression of PPARA mRNA]; Chenodeoxycholic Acid inhibits the reaction [tris(chloroethyl)phosphate results in decreased expression of PPARA protein] |
CTD |
PMID:15980055 PMID:27773935 PMID:33819548 PMID:35780845 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
increases expression multiple interactions |
EXP ISO |
Chenodeoxycholic Acid results in increased expression of PPARG mRNA Chenodeoxycholic Acid inhibits the reaction [tris(chloroethyl)phosphate results in increased expression of PPARG mRNA]; Chenodeoxycholic Acid inhibits the reaction [tris(chloroethyl)phosphate results in increased expression of PPARG protein] |
CTD |
PMID:15980055 PMID:27174168 PMID:35780845 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppp1r3c |
protein phosphatase 1, regulatory subunit 3C |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of PPP1R3C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of PPP1R3C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of PPP1R3C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of PPP1R3C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of PPP1R3C mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 1:234,460,958...234,465,961
Ensembl chr 1:234,460,652...234,465,961
|
|
G |
Prkd3 |
protein kinase D3 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of PRKD3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of PRKD3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of PRKD3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of PRKD3 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 6:16,032,507...16,108,444
Ensembl chr 6:16,032,585...16,108,443
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression multiple interactions |
ISO |
Chenodeoxycholic Acid results in increased expression of PTGS2 mRNA [SLCO1B3 protein results in increased transport of Chenodeoxycholic Acid] which results in increased expression of PTGS2 mRNA |
CTD |
PMID:18648741 PMID:21224055 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rab7a |
RAB7A, member RAS oncogene family |
decreases expression |
ISO |
Chenodeoxycholic Acid results in decreased expression of RAB7 protein |
CTD |
PMID:24189133 |
|
NCBI chr 4:120,461,966...120,510,756
Ensembl chr 4:120,461,963...120,506,889
|
|
G |
Rala |
RAS like proto-oncogene A |
multiple interactions |
ISO |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RALA mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RALA mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RALA mRNA |
CTD |
PMID:32152650 |
|
NCBI chr17:47,092,163...47,145,192
Ensembl chr17:47,092,207...47,144,063
|
|
G |
Rap1a |
RAP1A, member of RAS oncogene family |
multiple interactions |
ISO |
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of RAP1A mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of RAP1A mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 2:193,208,631...193,286,513
Ensembl chr 2:193,208,635...193,286,501
|
|
G |
Rara |
retinoic acid receptor, alpha |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of RARA mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of RARA mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RARA mRNA |
CTD |
PMID:33819548 |
|
NCBI chr10:83,883,490...83,928,932
Ensembl chr10:83,893,384...83,928,142
|
|
G |
Rasd1 |
ras related dexamethasone induced 1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of RASD1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of RASD1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of RASD1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr10:44,766,451...44,775,773
Ensembl chr10:44,766,455...44,768,186
|
|
G |
Rdh16 |
retinol dehydrogenase 16 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of RDH16 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of RDH16 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of RDH16 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of RDH16 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of RDH16 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 7:63,616,711...63,625,053
Ensembl chr 7:63,597,536...63,624,124
|
|
G |
Reep5 |
receptor accessory protein 5 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of REEP5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of REEP5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of REEP5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of REEP5 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr18:25,945,375...25,983,271
Ensembl chr18:25,945,381...25,976,509
|
|
G |
Ripk1 |
receptor interacting serine/threonine kinase 1 |
multiple interactions |
ISO |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RIPK1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RIPK1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RIPK1 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr17:30,839,639...30,871,824
Ensembl chr17:30,839,650...30,871,824
|
|
G |
Rora |
RAR-related orphan receptor A |
affects expression |
ISO |
Chenodeoxycholic Acid affects the expression of RORA mRNA |
CTD |
PMID:31437187 |
|
NCBI chr 8:69,301,635...70,034,741
Ensembl chr 8:69,301,733...70,025,931
|
|
G |
Rras2 |
RAS related 2 |
multiple interactions |
ISO |
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RRAS2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of RRAS2 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 1:168,233,693...168,303,111
Ensembl chr 1:168,233,693...168,303,111
|
|
G |
Scarb1 |
scavenger receptor class B, member 1 |
increases expression multiple interactions |
ISO |
Chenodeoxycholic Acid results in increased expression of SCARB1 mRNA [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SCARB1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SCARB1 mRNA |
CTD |
PMID:22540009 PMID:32152650 |
|
NCBI chr12:31,296,143...31,362,649
Ensembl chr12:31,296,156...31,362,647
|
|
G |
Scd |
stearoyl-CoA desaturase |
multiple interactions |
ISO |
Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of SCD1 protein] [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SCD mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of SCD mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of SCD mRNA |
CTD |
PMID:27773935 PMID:33819548 |
|
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
|
|
G |
Scp2 |
sterol carrier protein 2 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SCP2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SCP2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of SCP2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of SCP2 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 5:122,806,949...122,881,259
Ensembl chr 5:122,776,549...122,881,287
|
|
G |
Sdc2 |
syndecan 2 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of SDC2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SDC2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of SDC2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of SDC2 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 7:64,127,185...64,239,885
Ensembl chr 7:64,127,110...64,241,081
|
|
G |
Sele |
selectin E |
multiple interactions increases expression |
ISO |
BAY 11-7085 inhibits the reaction [Chenodeoxycholic Acid results in increased expression of SELE mRNA]; SB 203580 inhibits the reaction [Chenodeoxycholic Acid results in increased expression of SELE mRNA] |
CTD |
PMID:16582018 |
|
NCBI chr13:76,402,841...76,412,741
Ensembl chr13:76,403,304...76,412,741
|
|
G |
Serpine1 |
serpin family E member 1 |
multiple interactions increases expression |
ISO |
EGR1 promotes the reaction [Chenodeoxycholic Acid results in increased expression of SERPINE1 mRNA] [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SERPINE1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SERPINE1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of SERPINE1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of SERPINE1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of SERPINE1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of SERPINE1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SERPINE1 mRNA |
CTD |
PMID:21224055 PMID:32152650 PMID:33819548 |
|
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Sh3glb1 |
SH3 domain -containing GRB2-like endophilin B1 |
multiple interactions |
ISO |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SH3GLB1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SH3GLB1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SH3GLB1 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 2:233,750,838...233,784,817
Ensembl chr 2:233,750,838...233,784,784
|
|
G |
Slc10a1 |
solute carrier family 10 member 1 |
decreases expression multiple interactions |
ISO EXP |
Chenodeoxycholic Acid results in decreased expression of SLC10A1 mRNA Chenodeoxycholic Acid inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of SLC10A1 mRNA] [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of SLC10A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SLC10A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of SLC10A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of SLC10A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC10A1 mRNA [Chenodeoxycholic Acid co-treated with Ketoconazole] results in decreased expression of SLC10A1 mRNA; Chenodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in decreased expression of SLC10A1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Chenodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in decreased expression of SLC10A1 mRNA]] |
CTD |
PMID:25055961 PMID:27743861 PMID:30985903 PMID:32152650 PMID:32976922 PMID:33819548 More...
|
|
NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670
|
|
G |
Slc10a2 |
solute carrier family 10 member 2 |
multiple interactions |
ISO |
Chenodeoxycholic Acid inhibits the reaction [SLC10A2 protein results in increased transport of Taurocholic Acid] |
CTD |
PMID:25466967 |
|
NCBI chr16:84,386,528...84,409,475
Ensembl chr16:84,374,862...84,409,475
|
|
G |
Slc10a7 |
solute carrier family 10, member 7 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SLC10A7 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of SLC10A7 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of SLC10A7 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr19:29,183,143...29,407,470
Ensembl chr19:29,183,155...29,407,464
|
|
G |
Slc12a2 |
solute carrier family 12 member 2 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of SLC12A2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of SLC12A2 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr18:51,348,282...51,416,448
Ensembl chr18:51,348,302...51,416,440
|
|
G |
Slc17a1 |
solute carrier family 17 member 1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SLC17A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SLC17A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of SLC17A1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr17:41,219,461...41,255,199
Ensembl chr17:41,222,049...41,253,304
|
|
G |
Slc22a1 |
solute carrier family 22 member 1 |
decreases expression multiple interactions |
ISO |
Chenodeoxycholic Acid results in decreased expression of SLC22A1 mRNA [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of SLC22A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SLC22A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SLC22A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of SLC22A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of SLC22A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of SLC22A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SLC22A1 mRNA |
CTD |
PMID:27174168 PMID:33819548 |
|
NCBI chr 1:48,076,657...48,103,679
Ensembl chr 1:48,076,666...48,103,678
|
|
G |
Slc22a7 |
solute carrier family 22 member 7 |
decreases expression |
ISO |
Chenodeoxycholic Acid results in decreased expression of SLC22A7 mRNA |
CTD |
PMID:27174168 |
|
NCBI chr 9:14,547,073...14,554,354
Ensembl chr 9:14,547,849...14,553,921
|
|
G |
Slc27a5 |
solute carrier family 27 member 5 |
multiple interactions |
ISO |
Chenodeoxycholic Acid inhibits the reaction [SLC27A5 protein results in increased uptake of Fatty Acids] |
CTD |
PMID:22531947 |
|
NCBI chr 1:73,616,556...73,627,149
Ensembl chr 1:73,616,564...73,627,172
|
|
G |
Slc35b1 |
solute carrier family 35, member B1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of SLC35B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of SLC35B1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr10:80,327,921...80,335,279
Ensembl chr10:80,327,945...80,335,274
|
|
G |
Slc51a |
solute carrier family 51 member A |
multiple interactions increases expression |
ISO EXP |
7-hydroxytheonellasterol inhibits the reaction [Chenodeoxycholic Acid inhibits the reaction [NCOR1 protein binds to SLC51A promoter]]; 7-hydroxytheonellasterol inhibits the reaction [Chenodeoxycholic Acid results in increased expression of SLC51A mRNA]; [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51A mRNA; [Calcitriol co-treated with Chenodeoxycholic Acid] results in decreased expression of SLC51A mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51A mRNA; Chenodeoxycholic Acid inhibits the reaction [NCOR1 protein binds to SLC51A promoter]; Chenodeoxycholic Acid promotes the reaction [Oxygen deficiency results in increased expression of SLC51A mRNA]; epigallocatechin gallate inhibits the reaction [Chenodeoxycholic Acid results in increased expression of SLC51A mRNA]; HIF1A mutant form inhibits the reaction [Chenodeoxycholic Acid results in increased expression of SLC51A mRNA]; NR1H4 mutant form inhibits the reaction [Chenodeoxycholic Acid results in increased expression of SLC51A mRNA]; NR1H4 protein affects the reaction [Chenodeoxycholic Acid results in increased expression of SLC51A mRNA]; Oxygen deficiency promotes the reaction [Chenodeoxycholic Acid results in increased expression of SLC51A mRNA] Chenodeoxycholic Acid results in increased expression of SLC51A mRNA; Chenodeoxycholic Acid results in increased expression of SLC51A protein [Chenodeoxycholic Acid binds to NR1H4 protein] which results in increased expression of SLC51A mRNA |
CTD |
PMID:16423920 PMID:19562681 PMID:22178739 PMID:22291955 PMID:24703425 PMID:25055961 PMID:25582706 PMID:27174168 PMID:32152650 PMID:32294204 More...
|
|
NCBI chr11:68,299,086...68,313,485
Ensembl chr11:68,299,086...68,313,485
|
|
G |
Slc51b |
SLC51 subunit beta |
multiple interactions increases expression |
ISO EXP |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [Calcitriol co-treated with Chenodeoxycholic Acid] results in decreased expression of SLC51B mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SLC51B mRNA; epigallocatechin gallate inhibits the reaction [Chenodeoxycholic Acid results in increased expression of SLC51B mRNA]; NR1H4 mutant form inhibits the reaction [Chenodeoxycholic Acid results in increased expression of SLC51B mRNA]; NR1H4 protein affects the reaction [Chenodeoxycholic Acid results in increased expression of SLC51B mRNA] Chenodeoxycholic Acid results in increased expression of SLC51B mRNA; Chenodeoxycholic Acid results in increased expression of SLC51B protein [Chenodeoxycholic Acid binds to NR1H4 protein] which results in increased expression of SLC51B mRNA |
CTD |
PMID:16423920 PMID:19562681 PMID:22178739 PMID:24703425 PMID:25055961 PMID:27174168 PMID:32152650 PMID:32294204 More...
|
|
NCBI chr 8:65,931,891...65,939,953
Ensembl chr 8:65,931,890...65,940,145
|
|
G |
Slco1a4 |
solute carrier organic anion transporter family, member 1a4 |
decreases expression multiple interactions |
EXP |
Chenodeoxycholic Acid results in decreased expression of SLCO1A2 mRNA Chenodeoxycholic Acid inhibits the reaction [Ethinyl Estradiol results in decreased expression of SLCO1A2 mRNA] |
CTD |
PMID:27743861 |
|
NCBI chr 4:174,710,004...174,764,810
Ensembl chr 4:174,710,004...175,254,573
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family member 1B2 |
increases expression multiple interactions increases transport |
ISO |
Chenodeoxycholic Acid results in increased expression of SLCO1B2 mRNA Chenodeoxycholic Acid results in increased expression of SLCO1B3 mRNA [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SLCO1B3 mRNA; [SLCO1B3 protein results in increased transport of Chenodeoxycholic Acid] which results in increased expression of PTGS2 mRNA |
CTD |
PMID:18648741 PMID:25055961 PMID:25582706 PMID:27174168 PMID:33819548 |
|
NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981
|
|
G |
Socs3 |
suppressor of cytokine signaling 3 |
multiple interactions |
ISO |
Chenodeoxycholic Acid promotes the reaction [Carbon Tetrachloride results in decreased expression of SOCS3 mRNA] |
CTD |
PMID:25747392 |
|
NCBI chr10:103,193,909...103,197,322
Ensembl chr10:103,193,537...103,197,787
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions |
ISO |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SOD2 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SOD2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of SOD2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of SOD2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of SOD2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of SOD2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SOD2 mRNA |
CTD |
PMID:32152650 PMID:33819548 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sorl1 |
sortilin related receptor 1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SORL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SORL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of SORL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of SORL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of SORL1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 8:42,341,704...42,504,435
Ensembl chr 8:42,341,704...42,504,513
|
|
G |
Sqstm1 |
sequestosome 1 |
increases expression multiple interactions |
ISO |
Chenodeoxycholic Acid results in increased expression of SQSTM1 protein [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SQSTM1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SQSTM1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of SQSTM1 mRNA |
CTD |
PMID:24189133 PMID:32152650 |
|
NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
decreases expression multiple interactions |
ISO |
Chenodeoxycholic Acid results in decreased expression of SREBF1 mRNA [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SREBF1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of SREBF1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of SREBF1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of SREBF1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of SREBF1 mRNA Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of SREBF1 protein]; Chenodeoxycholic Acid inhibits the reaction [tris(chloroethyl)phosphate results in increased expression of SREBF1 mRNA]; Chenodeoxycholic Acid inhibits the reaction [tris(chloroethyl)phosphate results in increased expression of SREBF1 protein] |
CTD |
PMID:16269825 PMID:27773935 PMID:33819548 PMID:35780845 |
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Srp72 |
signal recognition particle 72 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of SRP72 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of SRP72 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of SRP72 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr14:31,168,175...31,195,717
Ensembl chr14:31,168,293...31,195,729
|
|
G |
Stip1 |
stress-induced phosphoprotein 1 |
multiple interactions |
ISO |
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of STIP1 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 1:204,209,433...204,228,452
Ensembl chr 1:204,178,932...204,228,476
|
|
G |
Stk11 |
serine/threonine kinase 11 |
multiple interactions |
ISO |
Chenodeoxycholic Acid inhibits the reaction [1-Naphthylisothiocyanate results in increased phosphorylation of STK11 protein] |
CTD |
PMID:32976922 |
|
NCBI chr 7:9,574,553...9,591,315
Ensembl chr 7:9,575,269...9,591,315
|
|
G |
Sult1b1 |
sulfotransferase family 1B member 1 |
decreases expression |
ISO |
Chenodeoxycholic Acid results in decreased expression of SULT1B1 mRNA |
CTD |
PMID:27174168 |
|
NCBI chr14:20,492,763...20,505,491
Ensembl chr14:20,492,708...20,505,483
|
|
G |
Sult1c2a |
sulfotransferase family 1C member 2A |
increases expression |
ISO |
Chenodeoxycholic Acid results in increased expression of SULT1C2 mRNA |
CTD |
PMID:27174168 |
|
NCBI chr 9:6,873,697...6,904,736
Ensembl chr 9:6,874,249...6,904,734
|
|
G |
Sult1e1 |
sulfotransferase family 1E member 1 |
decreases expression |
ISO |
Chenodeoxycholic Acid results in decreased expression of SULT1E1 mRNA |
CTD |
PMID:27174168 |
|
NCBI chr14:20,422,324...20,439,562
Ensembl chr14:20,422,324...20,439,275
|
|
G |
Sult2a1 |
sulfotransferase family 2A member 1 |
increases sulfation multiple interactions decreases expression |
ISO |
SULT2A1 protein results in increased sulfation of Chenodeoxycholic Acid [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of SULT2A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of SULT2A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of SULT2A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of SULT2A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of SULT2A1 mRNA NR1H4 protein promotes the reaction [Chenodeoxycholic Acid results in decreased expression of SULT2A1 mRNA] Chenodeoxycholic Acid results in decreased expression of SULT2A1 mRNA; Chenodeoxycholic Acid results in decreased expression of SULT2A1 protein |
CTD |
PMID:16946559 PMID:20102295 PMID:32152650 PMID:33819548 |
|
NCBI chr 1:75,451,178...75,508,113
Ensembl chr 1:74,911,100...75,508,134
|
|
G |
Tef |
TEF transcription factor, PAR bZIP family member |
increases expression |
ISO |
Chenodeoxycholic Acid results in increased expression of TEF mRNA |
CTD |
PMID:19072826 |
|
NCBI chr 7:113,317,191...113,341,783
Ensembl chr 7:113,317,283...113,341,783
|
|
G |
Tfpi |
tissue factor pathway inhibitor |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of TFPI mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of TFPI mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of TFPI mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of TFPI mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of TFPI mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 3:69,533,156...69,582,547
Ensembl chr 3:69,533,156...69,576,880
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of TGFB1 mRNA]; Chenodeoxycholic Acid inhibits the reaction [alisol A 24-acetate inhibits the reaction [[Choline deficiency co-treated with Methionine deficiency] results in increased expression of TGFB1 mRNA]] |
CTD |
PMID:27773935 PMID:29883724 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
multiple interactions |
ISO |
Chenodeoxycholic Acid affects the reaction [alisol A 24-acetate inhibits the reaction [[Choline deficiency co-treated with Methionine deficiency] results in increased expression of TIMP1 mRNA]]; Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of TIMP1 mRNA] |
CTD |
PMID:27773935 PMID:29883724 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Tjp2 |
tight junction protein 2 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of TJP2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of TJP2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of TJP2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of TJP2 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 1:221,709,745...221,838,291
Ensembl chr 1:221,709,745...221,838,295
|
|
G |
Tlr3 |
toll-like receptor 3 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of TLR3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of TLR3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of TLR3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of TLR3 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr16:46,821,980...46,837,900
Ensembl chr16:46,822,039...46,836,545
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of TLR4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of TLR4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of TLR4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of TLR4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of TLR4 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Tnfrsf10b |
TNF receptor superfamily member 10b |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of TNFRSF10A mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of TNFRSF10A mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of TNFRSF10A mRNA |
CTD |
PMID:33819548 |
|
NCBI chr15:44,840,386...44,868,318
Ensembl chr15:44,840,386...44,867,467
|
|
G |
Tnfrsf9 |
TNF receptor superfamily member 9 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of TNFRSF9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of TNFRSF9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of TNFRSF9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of TNFRSF9 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 5:161,381,662...161,408,003
Ensembl chr 5:161,381,662...161,408,000
|
|
G |
Tnfsf10 |
TNF superfamily member 10 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of TNFSF10 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of TNFSF10 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of TNFSF10 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of TNFSF10 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of TNFSF10 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of TNFSF10 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135
|
|
G |
Tnfsf11 |
TNF superfamily member 11 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of TNFSF11 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of TNFSF11 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of TNFSF11 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of TNFSF11 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of TNFSF11 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445
|
|
G |
Txn1 |
thioredoxin 1 |
multiple interactions increases expression |
ISO |
[Chenodeoxycholic Acid results in increased activity of NFE2L2 protein] which results in increased expression of TXN mRNA Chenodeoxycholic Acid results in increased expression of TXN protein |
CTD |
PMID:17724089 |
|
NCBI chr 5:72,712,334...72,724,564
Ensembl chr 5:72,711,933...72,724,629
|
|
G |
Uba5 |
ubiquitin-like modifier activating enzyme 5 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of UBA5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of UBA5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of UBA5 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 8:104,665,241...104,680,915
Ensembl chr 8:104,665,046...104,680,894
|
|
G |
Ube2k |
ubiquitin-conjugating enzyme E2K |
multiple interactions |
ISO |
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of UBE2K mRNA |
CTD |
PMID:32152650 |
|
NCBI chr14:42,658,016...42,718,899
Ensembl chr14:42,658,016...42,718,630
|
|
G |
Ugp2 |
UDP-glucose pyrophosphorylase 2 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of UGP2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of UGP2 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr14:95,456,330...95,497,483
Ensembl chr14:95,456,330...95,496,830
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
increases expression multiple interactions |
ISO |
Chenodeoxycholic Acid results in increased expression of UGT1A1 mRNA [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of UGT1A1 mRNA Chenodeoxycholic Acid inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of UGT1A1 mRNA]; Chenodeoxycholic Acid inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of UGT1A1 protein] |
CTD |
PMID:27174168 PMID:32976922 PMID:33819548 |
|
NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a2 |
UDP glucuronosyltransferase 1 family, polypeptide A2 |
multiple interactions increases expression increases glucuronidation |
ISO |
[Chenodeoxycholic Acid promotes the reaction [NR1H4 protein binds to UGT1A3 promoter]] which results in increased expression of UGT1A3 mRNA; Chenodeoxycholic Acid promotes the reaction [NR1H4 protein binds to UGT1A3 promoter]; shikonin inhibits the reaction [UGT1A3 protein results in increased glucuronidation of Chenodeoxycholic Acid]; UGT1A3 protein affects the reaction [Chenodeoxycholic Acid affects the activity of NR1H4 protein] Chenodeoxycholic Acid results in increased expression of UGT1A3 mRNA |
CTD |
PMID:17058234 PMID:20189675 PMID:27174168 PMID:31128210 |
|
NCBI chr 9:88,791,216...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a6 |
UDP glucuronosyltransferase family 1 member A6 |
decreases expression |
ISO |
Chenodeoxycholic Acid results in decreased expression of UGT1A6 mRNA |
CTD |
PMID:27174168 |
|
NCBI chr 9:88,747,213...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a9 |
UDP glucuronosyltransferase family 1 member A9 |
decreases expression |
ISO |
Chenodeoxycholic Acid results in decreased expression of UGT1A9 mRNA |
CTD |
PMID:27174168 |
|
NCBI chr 9:88,696,981...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt2a3 |
UDP glucuronosyltransferase family 2 member A3 |
decreases expression |
ISO |
Chenodeoxycholic Acid results in decreased expression of UGT2A3 mRNA |
CTD |
PMID:27174168 |
|
NCBI chr14:20,572,793...20,590,795
Ensembl chr14:20,572,808...20,590,729
|
|
G |
Ugt2b7 |
UDP glucuronosyltransferase family 2 member B7 |
decreases expression |
ISO |
Chenodeoxycholic Acid results in decreased expression of UGT2B7 mRNA |
CTD |
PMID:15821044 |
|
NCBI chr14:20,896,682...20,919,604
Ensembl chr14:20,896,682...20,919,604
|
|
G |
Usp14 |
ubiquitin specific peptidase 14 |
multiple interactions |
ISO |
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of USP14 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr18:1,018,111...1,057,727
Ensembl chr18:1,019,400...1,057,519
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
increases expression multiple interactions |
ISO |
Chenodeoxycholic Acid results in increased expression of VCAM1 mRNA Chenodeoxycholic Acid inhibits the reaction [[Methionine deficiency co-treated with Choline deficiency] results in increased expression of VCAM1 mRNA] BAY 11-7085 inhibits the reaction [Chenodeoxycholic Acid results in increased expression of VCAM1 mRNA]; SB 203580 inhibits the reaction [Chenodeoxycholic Acid results in increased expression of VCAM1 mRNA] Chenodeoxycholic Acid results in increased expression of VCAM1 mRNA; Chenodeoxycholic Acid results in increased expression of VCAM1 protein |
CTD |
PMID:16582018 PMID:21224055 PMID:27773935 |
|
NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
|
|
G |
Vcp |
valosin-containing protein |
multiple interactions |
ISO |
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of VCP mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 5:57,210,167...57,229,571
Ensembl chr 5:57,210,168...57,229,571
|
|
G |
Vdr |
vitamin D receptor |
multiple interactions increases expression |
EXP ISO |
bisindolylmaleimide I inhibits the reaction [Chenodeoxycholic Acid results in increased expression of VDR mRNA]; Chenodeoxycholic Acid promotes the reaction [Calcitriol results in increased expression of VDR mRNA] |
CTD |
PMID:20006981 |
|
NCBI chr 7:128,987,981...129,037,677
Ensembl chr 7:128,987,981...129,037,677
|
|
G |
Vipr1 |
vasoactive intestinal peptide receptor 1 |
increases expression |
ISO |
Chenodeoxycholic Acid results in increased expression of VIPR1 mRNA; Chenodeoxycholic Acid results in increased expression of VIPR1 protein |
CTD |
PMID:16037943 |
|
NCBI chr 8:121,303,739...121,339,587
Ensembl chr 8:121,310,248...121,339,585
|
|
|
G |
Efna1 |
ephrin A1 |
multiple interactions |
ISO |
cholanic acid inhibits the reaction [EFNA1 protein binds to and results in increased phosphorylation of and results in increased activity of EPHA2 protein] |
CTD |
PMID:22529030 |
|
NCBI chr 2:174,681,676...174,689,061
Ensembl chr 2:174,681,682...174,690,866
|
|
G |
Epha2 |
Eph receptor A2 |
multiple interactions |
ISO |
cholanic acid binds to and results in decreased activity of EPHA2 protein; cholanic acid inhibits the reaction [EFNA1 protein binds to and results in increased phosphorylation of and results in increased activity of EPHA2 protein] |
CTD |
PMID:22529030 |
|
NCBI chr 5:153,605,644...153,634,115
Ensembl chr 5:153,605,644...153,634,117
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
multiple interactions |
ISO |
cholanic acid binds to and results in increased activity of NR1H4 protein |
CTD |
PMID:15489543 |
|
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Vdr |
vitamin D receptor |
multiple interactions |
ISO |
cholanic acid binds to and results in increased activity of VDR protein; cholanic acid binds to and results in increased activity of VDR protein mutant form |
CTD |
PMID:21291553 |
|
NCBI chr 7:128,987,981...129,037,677
Ensembl chr 7:128,987,981...129,037,677
|
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
increases expression multiple interactions |
ISO EXP |
Cholic Acid results in increased expression of ABCA1 mRNA [Cholesterol, Dietary co-treated with Cholic Acid] results in increased expression of ABCA1 mRNA |
CTD |
PMID:14684380 PMID:15694933 |
|
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Abca8 |
ATP binding cassette subfamily A member 8 |
multiple interactions |
ISO |
[NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ABCA8 mRNA |
CTD |
PMID:30996006 |
|
NCBI chr10:94,917,520...94,991,199
Ensembl chr10:94,917,520...94,990,988
|
|
G |
Abca9 |
ATP binding cassette subfamily A member 9 |
multiple interactions |
ISO |
[NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ABCA9 mRNA |
CTD |
PMID:30996006 |
|
NCBI chr10:95,077,615...95,137,751
Ensembl chr10:95,079,058...95,139,608
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
increases expression decreases activity multiple interactions |
EXP ISO |
Cholic Acid results in increased expression of ABCB11 mRNA Cholic Acid results in increased expression of ABCB11 mRNA; Cholic Acid results in increased expression of ABCB11 protein Cholic Acid results in decreased activity of ABCB11 protein Cholic Acid inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid] [Cholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of ABCB11 mRNA; [NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ABCB11 mRNA; epiallopregnanolone sulfate inhibits the reaction [Cholic Acid results in increased expression of ABCB11 mRNA] [Cholesterol, Dietary co-treated with Cholic Acid] results in increased expression of ABCB11 mRNA |
CTD |
PMID:11438506 PMID:12971955 PMID:14684380 PMID:15466244 PMID:15694933 PMID:22540009 PMID:22961653 PMID:24014644 PMID:25055961 PMID:25582706 PMID:30996006 More...
|
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases expression |
ISO |
Cholic Acid results in increased expression of ABCB1A mRNA; Cholic Acid results in increased expression of ABCB1A protein |
CTD |
PMID:11438506 PMID:17521389 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcb1b |
ATP-binding cassette, sub-family B member 1B |
increases expression |
ISO |
Cholic Acid results in increased expression of ABCB1B mRNA; Cholic Acid results in increased expression of ABCB1B protein |
CTD |
PMID:11438506 |
|
NCBI chr 4:25,242,761...25,325,194
Ensembl chr 4:25,242,798...25,325,199
|
|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
affects secretion increases expression multiple interactions |
ISO |
ABCB4 affects the secretion of Cholic Acid Cholic Acid results in increased expression of ABCB4 mRNA epiallopregnanolone sulfate inhibits the reaction [Cholic Acid results in increased expression of ABCB4 mRNA] |
CTD |
PMID:12967592 PMID:22961653 PMID:25582706 |
|
NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
multiple interactions |
ISO |
Cholic Acid inhibits the reaction [ABCC1 protein results in increased export of 2',7'-bis-(carboxypropyl)-5(6)-carboxyfluorescein] |
CTD |
PMID:16101123 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
increases expression |
ISO |
Cholic Acid results in increased expression of ABCC2 mRNA Cholic Acid results in increased expression of ABCC2 mRNA; Cholic Acid results in increased expression of ABCC2 protein |
CTD |
PMID:11438506 PMID:12971955 PMID:15694933 PMID:25055961 PMID:25582706 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
increases expression |
ISO |
Cholic Acid results in increased expression of ABCC3 mRNA |
CTD |
PMID:12971955 PMID:25055961 PMID:25582706 |
|
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Abcg1 |
ATP binding cassette subfamily G member 1 |
multiple interactions |
ISO |
[NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ABCG1 mRNA |
CTD |
PMID:30996006 |
|
NCBI chr20:9,126,687...9,182,948
Ensembl chr20:9,126,687...9,182,948
|
|
G |
Abcg5 |
ATP binding cassette subfamily G member 5 |
increases expression multiple interactions |
ISO |
Cholic Acid results in increased expression of ABCG5 mRNA [NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ABCG5 mRNA |
CTD |
PMID:25055961 PMID:25582706 PMID:30996006 |
|
NCBI chr 6:9,965,118...9,990,563
Ensembl chr 6:9,965,118...9,990,563
|
|
G |
Abcg8 |
ATP binding cassette subfamily G member 8 |
increases expression multiple interactions |
ISO |
Cholic Acid results in increased expression of ABCG8 mRNA [NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ABCG8 mRNA |
CTD |
PMID:25582706 PMID:30996006 |
|
NCBI chr 6:9,945,629...9,964,912
Ensembl chr 6:9,945,629...9,964,912
|
|
G |
Acaca |
acetyl-CoA carboxylase alpha |
multiple interactions |
EXP |
[Cholesterol, Dietary co-treated with Cholic Acid] results in increased expression of ACACA mRNA; zingerone inhibits the reaction [[Cholesterol, Dietary co-treated with Cholic Acid] results in increased expression of ACACA mRNA] |
CTD |
PMID:33845646 |
|
NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
|
|
G |
Acox1 |
acyl-CoA oxidase 1 |
multiple interactions |
EXP |
[Cholesterol, Dietary co-treated with Cholic Acid] results in decreased expression of ACOX1 mRNA; zingerone inhibits the reaction [[Cholesterol, Dietary co-treated with Cholic Acid] results in decreased expression of ACOX1 mRNA] |
CTD |
PMID:33845646 |
|
NCBI chr10:101,406,197...101,431,252
Ensembl chr10:101,406,197...101,431,232
|
|
G |
Acsl1 |
acyl-CoA synthetase long-chain family member 1 |
multiple interactions |
EXP |
[Cholesterol, Dietary co-treated with Cholic Acid] results in increased expression of ACSL1 mRNA; zingerone inhibits the reaction [[Cholesterol, Dietary co-treated with Cholic Acid] results in increased expression of ACSL1 mRNA] |
CTD |
PMID:33845646 |
|
NCBI chr16:45,755,246...45,821,541
Ensembl chr16:45,755,254...45,821,541
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
ISO |
[bisphenol A co-treated with Dietary Fats co-treated with Cholesterol co-treated with Cholic Acid] results in increased expression of ACTA2 protein; Acetylcysteine inhibits the reaction [[bisphenol A co-treated with Dietary Fats co-treated with Cholesterol co-treated with Cholic Acid] results in increased expression of ACTA2 protein] |
CTD |
PMID:35622622 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions increases secretion increases abundance |
ISO |
AHR gene mutant form inhibits the reaction [Tetrachlorodibenzodioxin results in decreased secretion of Cholic Acid] AHR gene mutant form results in increased secretion of Cholic Acid AHR gene mutant form results in increased abundance of Cholic Acid |
CTD |
PMID:29452137 PMID:32679164 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
AKR1C3l1 |
aldo-keto reductase family 1 member C3-like 1 |
increases abundance |
EXP |
AKR1C4 protein results in increased abundance of Cholic Acid |
CTD |
PMID:3468121 |
|
NCBI chr17:65,847,580...65,881,488
Ensembl chr17:65,835,634...65,881,488
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
Cholic Acid results in increased activity of and results in increased phosphorylation of AKT1 protein; Diethylnitrosamine inhibits the reaction [Cholic Acid results in increased activity of and results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:27151938 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Atp8b1 |
ATPase phospholipid transporting 8B1 |
multiple interactions |
ISO |
[NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ATP8B1 mRNA |
CTD |
PMID:30996006 |
|
NCBI chr18:58,016,382...58,157,213
Ensembl chr18:58,018,268...58,157,396
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
[bisphenol A co-treated with Dietary Fats co-treated with Cholesterol co-treated with Cholic Acid] results in increased cleavage of CASP3 protein; Acetylcysteine inhibits the reaction [[bisphenol A co-treated with Dietary Fats co-treated with Cholesterol co-treated with Cholic Acid] results in increased cleavage of CASP3 protein]; Cholic Acid inhibits the reaction [Diethylnitrosamine results in increased cleavage of CASP3 protein] |
CTD |
PMID:27151938 PMID:35622622 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cat |
catalase |
multiple interactions |
EXP |
[Cholesterol co-treated with Cholic Acid] results in decreased activity of CAT protein; [Cholesterol, Dietary co-treated with Cholic Acid] results in decreased activity of CAT protein; lupeol inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased activity of CAT protein]; lupeol linoleate inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased activity of CAT protein]; zingerone inhibits the reaction [[Cholesterol, Dietary co-treated with Cholic Acid] results in decreased activity of CAT protein] |
CTD |
PMID:16933029 PMID:33845646 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions increases expression |
ISO |
[Diethylnitrosamine co-treated with Cholic Acid] results in increased expression of CCND1 protein Cholic Acid results in increased expression of CCND1 protein |
CTD |
PMID:27151938 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Cd36 |
CD36 molecule |
multiple interactions |
ISO |
[bisphenol A co-treated with Dietary Fats co-treated with Cholesterol co-treated with Cholic Acid] results in increased expression of CD36 protein; Acetylcysteine inhibits the reaction [[bisphenol A co-treated with Dietary Fats co-treated with Cholesterol co-treated with Cholic Acid] results in increased expression of CD36 protein] |
CTD |
PMID:35622622 |
|
NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
decreases expression multiple interactions |
ISO |
Cholic Acid results in decreased expression of CDKN1A protein [Diethylnitrosamine co-treated with Cholic Acid] results in decreased expression of CDKN1A protein |
CTD |
PMID:27151938 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Chek1 |
checkpoint kinase 1 |
increases expression |
ISO |
Cholic Acid results in increased expression of CHEK1 protein |
CTD |
PMID:20025956 |
|
NCBI chr 8:36,420,565...36,443,477
Ensembl chr 8:36,420,569...36,441,009
|
|
G |
Chrm2 |
cholinergic receptor, muscarinic 2 |
increases expression |
EXP |
Cholic Acid results in increased expression of CHRM2 mRNA |
CTD |
PMID:35584729 |
|
NCBI chr 4:65,015,408...65,149,104
Ensembl chr 4:65,014,144...65,149,103
|
|
G |
Cldn1 |
claudin 1 |
decreases expression |
EXP |
Cholic Acid results in decreased expression of CLDN1 mRNA; Cholic Acid results in decreased expression of CLDN1 protein |
CTD |
PMID:35584729 |
|
NCBI chr11:74,421,569...74,436,728
Ensembl chr11:74,421,569...74,436,724
|
|
G |
Cldn2 |
claudin 2 |
decreases expression |
EXP |
Cholic Acid results in decreased expression of CLDN2 mRNA; Cholic Acid results in decreased expression of CLDN2 protein |
CTD |
PMID:35584729 |
|
NCBI chr X:103,459,870...103,473,794
Ensembl chr X:103,459,780...103,474,838
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
multiple interactions |
EXP |
[Cholesterol, Dietary co-treated with Cholic Acid] results in decreased expression of CPT1A mRNA; zingerone inhibits the reaction [[Cholesterol, Dietary co-treated with Cholic Acid] results in decreased expression of CPT1A mRNA] |
CTD |
PMID:33845646 |
|
NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
decreases expression |
EXP ISO |
Cholic Acid results in decreased expression of CYP27A1 mRNA |
CTD |
PMID:7832767 PMID:25582706 |
|
NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551
|
|
G |
Cyp2a1 |
cytochrome P450, family 2, subfamily a, polypeptide 1 |
decreases activity |
EXP |
Cholic Acid results in decreased activity of CYP2A1 protein |
CTD |
PMID:8889968 |
|
NCBI chr 1:82,231,611...82,244,887
Ensembl chr 1:82,231,611...82,244,887
|
|
G |
Cyp2a3 |
cytochrome P450, family 2, subfamily a, polypeptide 3 |
increases expression |
ISO |
Cholic Acid results in increased expression of CYP2A4 mRNA |
CTD |
PMID:17521389 |
|
NCBI chr 1:82,171,914...82,179,980
Ensembl chr 1:82,169,949...82,179,979
|
|
G |
Cyp2b2 |
cytochrome P450, family 2, subfamily b, polypeptide 2 |
increases expression |
ISO |
Cholic Acid results in increased expression of CYP2B13 mRNA |
CTD |
PMID:17521389 |
|
NCBI chr 1:81,594,534...81,608,567
Ensembl chr 1:81,594,555...81,608,566
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
increases expression |
ISO |
Cholic Acid results in increased expression of CYP2B10 mRNA |
CTD |
PMID:17521389 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
decreases activity |
EXP |
Cholic Acid results in decreased activity of CYP2C11 protein |
CTD |
PMID:8889968 |
|
NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
decreases activity multiple interactions |
EXP ISO |
Cholic Acid results in decreased activity of CYP3A2 protein [CYP3A23-3A1 gene mutant form co-treated with CYP3A2 gene mutant form] results in increased abundance of Cholic Acid Cholic Acid metabolite results in decreased activity of CYP3A4 protein Cholic Acid promotes the reaction [CYP3A4 protein results in increased oxidation of 7-benzyloxy-4-trifluoromethylcoumarin] |
CTD |
PMID:8889968 PMID:19299527 PMID:27871908 PMID:34461081 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a23-3a1 |
cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 |
multiple interactions |
EXP |
[CYP3A23-3A1 gene mutant form co-treated with CYP3A2 gene mutant form] results in increased abundance of Cholic Acid |
CTD |
PMID:34461081 |
|
NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030 Ensembl chr12:9,254,475...9,285,030
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
multiple interactions decreases expression |
EXP ISO |
[Cholesterol, Dietary co-treated with Cholic Acid] results in decreased activity of CYP7A1 protein; [Cholesterol, Dietary co-treated with Cholic Acid] results in decreased expression of CYP7A1 mRNA Cholic Acid results in decreased expression of CYP7A1 mRNA [Cholic Acid binds to and results in increased activity of NR1H4 protein] which results in decreased expression of CYP7A1 mRNA |
CTD |
PMID:12072388 PMID:14684380 PMID:15694933 PMID:17521389 PMID:20671298 PMID:22540009 PMID:25055961 PMID:25582706 More...
|
|
NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
|
|
G |
Cyp7b1 |
cytochrome P450 family 7 subfamily B member 1 |
decreases expression |
ISO |
Cholic Acid results in decreased expression of CYP7B1 mRNA |
CTD |
PMID:20671298 |
|
NCBI chr 2:100,502,791...100,669,713
Ensembl chr 2:100,502,791...100,669,698
|
|
G |
Cyp8b1 |
cytochrome P450 family 8 subfamily B member 1 |
decreases expression |
ISO |
Cholic Acid results in decreased expression of CYP8B1 mRNA |
CTD |
PMID:17521389 PMID:25055961 PMID:25582706 |
|
NCBI chr 8:121,578,123...121,580,093
Ensembl chr 8:121,557,062...121,580,166
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions |
ISO |
[bisphenol A co-treated with Dietary Fats co-treated with Cholesterol co-treated with Cholic Acid] results in increased expression of DDIT3 protein; Acetylcysteine inhibits the reaction [[bisphenol A co-treated with Dietary Fats co-treated with Cholesterol co-treated with Cholic Acid] results in increased expression of DDIT3 protein] |
CTD |
PMID:35622622 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Fabp6 |
fatty acid binding protein 6 |
increases expression |
ISO EXP |
Cholic Acid results in increased expression of FABP6 mRNA |
CTD |
PMID:25582706 PMID:35584729 |
|
NCBI chr10:28,063,603...28,068,276
Ensembl chr10:28,063,603...28,068,282
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions |
EXP |
[Cholesterol, Dietary co-treated with Cholic Acid] results in increased expression of FASN mRNA; zingerone inhibits the reaction [[Cholesterol, Dietary co-treated with Cholic Acid] results in increased expression of FASN mRNA] |
CTD |
PMID:33845646 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Fgf19 |
fibroblast growth factor 19 |
multiple interactions increases expression |
ISO |
[[Cholic Acid results in increased activity of NR1H4 protein] which binds to FGF19 promoter] which results in increased expression of FGF19 mRNA; [Cholic Acid results in increased activity of NR1H4 protein] which binds to FGF19 promoter Cholic Acid results in increased expression of FGF15 mRNA Cholic Acid results in increased expression of FGF19 mRNA |
CTD |
PMID:22561792 PMID:25055961 PMID:25582706 |
|
NCBI chr 1:200,056,526...200,060,980
Ensembl chr 1:200,056,644...200,060,287
|
|
G |
Fmo3 |
flavin containing dimethylaniline monoxygenase 3 |
increases expression |
ISO |
Cholic Acid results in increased expression of FMO3 mRNA |
CTD |
PMID:17521389 |
|
NCBI chr13:75,309,367...75,334,915
Ensembl chr13:75,309,374...75,328,028
|
|
G |
Fmo4 |
flavin containing dimethylaniline monoxygenase 4 |
increases expression |
ISO |
Cholic Acid results in increased expression of FMO4 mRNA |
CTD |
PMID:17521389 |
|
NCBI chr13:75,154,683...75,172,874
Ensembl chr13:75,154,684...75,172,874
|
|
G |
Fosl1 |
FOS like 1, AP-1 transcription factor subunit |
increases expression |
ISO |
Cholic Acid results in increased expression of FOSL1 protein |
CTD |
PMID:20025956 |
|
NCBI chr 1:202,754,549...202,763,057
Ensembl chr 1:202,754,529...202,764,930
|
|
G |
Gpbar1 |
G protein-coupled bile acid receptor 1 |
multiple interactions increases expression |
ISO |
Cholic Acid binds to and results in increased activity of GPBAR1 protein Cholic Acid results in increased expression of GPBAR1 mRNA |
CTD |
PMID:18180267 PMID:25055961 |
|
NCBI chr 9:75,860,758...75,863,260
Ensembl chr 9:75,860,677...75,863,168
|
|
G |
Gsta1 |
glutathione S-transferase alpha 1 |
multiple interactions |
EXP |
Cholic Acid binds to [GSTA1 protein co-treated with GSTA1 protein]; Cholic Acid binds to [GSTA3 protein co-treated with GSTA1 protein]; Glutathione inhibits the reaction [Cholic Acid binds to [GSTA3 protein co-treated with GSTA1 protein]] |
CTD |
PMID:3783048 |
|
NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121
|
|
G |
Gsta2 |
glutathione S-transferase alpha 2 |
increases expression |
ISO |
Cholic Acid results in increased expression of GSTA2 mRNA |
CTD |
PMID:17521389 |
|
NCBI chr 8:79,184,535...79,196,827
Ensembl chr 8:79,184,322...79,196,798
|
|
G |
Gsta3 |
glutathione S-transferase alpha 3 |
multiple interactions |
EXP |
Cholic Acid binds to [GSTA3 protein co-treated with GSTA1 protein]; Glutathione inhibits the reaction [Cholic Acid binds to [GSTA3 protein co-treated with GSTA1 protein]] |
CTD |
PMID:3783048 |
|
NCBI chr 9:23,658,574...23,684,240
Ensembl chr 9:23,658,574...23,684,240
|
|
G |
Gsta4 |
glutathione S-transferase alpha 4 |
multiple interactions |
EXP |
Cholic Acid binds to and results in decreased activity of GSTA4 protein |
CTD |
PMID:3954743 |
|
NCBI chr 8:79,066,967...79,084,193
Ensembl chr 8:79,066,934...79,084,182
|
|
G |
Gstm1 |
glutathione S-transferase mu 1 |
multiple interactions |
EXP |
Cholic Acid binds to and results in decreased activity of GSTM1 protein |
CTD |
PMID:3954743 |
|
NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411
|
|
G |
Gstm2 |
glutathione S-transferase mu 2 |
multiple interactions increases expression |
EXP ISO |
Cholic Acid binds to and results in decreased activity of GSTM2 protein Cholic Acid results in increased expression of GSTM2 mRNA |
CTD |
PMID:3954743 PMID:17521389 |
|
NCBI chr 2:195,624,015...195,628,774
Ensembl chr 2:195,544,426...195,628,961
|
|
G |
Gstm5 |
glutathione S-transferase, mu 5 |
increases expression |
ISO |
Cholic Acid results in increased expression of GSTM3 mRNA |
CTD |
PMID:17521389 |
|
NCBI chr 2:195,531,599...195,534,562
Ensembl chr 2:195,531,495...195,534,553
|
|
G |
Hells |
helicase, lymphoid specific |
increases expression |
ISO |
Cholic Acid results in increased expression of HELLS protein |
CTD |
PMID:20025956 |
|
NCBI chr 1:236,701,704...236,748,239
Ensembl chr 1:236,701,758...236,746,844
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
multiple interactions |
EXP |
[Cholesterol co-treated with Cholic Acid] results in decreased expression of HMGCR mRNA; [Cholesterol co-treated with Cholic Acid] results in increased activity of HMGCR protein; Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased expression of HMGCR mRNA]; Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in increased activity of HMGCR protein]; Proanthocyanidins inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased expression of HMGCR mRNA]; Proanthocyanidins inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in increased activity of HMGCR protein] |
CTD |
PMID:30273964 |
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Hnf4a |
hepatocyte nuclear factor 4, alpha |
multiple interactions |
EXP |
[Cholesterol co-treated with Cholic Acid] results in decreased expression of HNF4A mRNA; Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased expression of HNF4A mRNA]; Proanthocyanidins inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased expression of HNF4A mRNA] |
CTD |
PMID:30273964 |
|
NCBI chr 3:152,186,787...152,248,320
Ensembl chr 3:152,186,787...152,248,320
|
|
G |
Hsd11b1 |
hydroxysteroid 11-beta dehydrogenase 1 |
increases abundance |
ISO |
HSD11B1 gene mutant form results in increased abundance of Cholic Acid |
CTD |
PMID:25061560 |
|
NCBI chr13:104,728,539...104,798,884
Ensembl chr13:104,728,539...104,788,687
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
[Diethylnitrosamine co-treated with Cholic Acid] results in increased expression of IL1B mRNA; IL1B protein inhibits the reaction [Cholic Acid results in increased expression of NR0B2 mRNA] |
CTD |
PMID:12072388 PMID:27151938 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il1rl1 |
interleukin 1 receptor-like 1 |
increases expression |
ISO |
Cholic Acid results in increased expression of IL1RL1 protein |
CTD |
PMID:20025956 |
|
NCBI chr 9:42,661,694...42,727,266
Ensembl chr 9:42,697,192...42,727,256
|
|
G |
Lcat |
lecithin cholesterol acyltransferase |
multiple interactions |
EXP |
[Cholesterol co-treated with Cholic Acid] results in increased activity of LCAT protein; Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in increased activity of LCAT protein]; Proanthocyanidins inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in increased activity of LCAT protein] |
CTD |
PMID:30273964 |
|
NCBI chr19:33,834,748...33,838,214
Ensembl chr19:33,834,403...33,838,231
|
|
G |
Ldlr |
low density lipoprotein receptor |
multiple interactions |
EXP |
[Cholesterol co-treated with Cholic Acid] results in decreased expression of LDLR mRNA; Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased expression of LDLR mRNA]; Proanthocyanidins inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased expression of LDLR mRNA] |
CTD |
PMID:30273964 |
|
NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580
|
|
G |
Lpl |
lipoprotein lipase |
multiple interactions |
EXP |
[Cholesterol co-treated with Cholic Acid] results in increased activity of LPL protein; [Cholesterol, Dietary co-treated with Cholic Acid] results in increased expression of LPL mRNA; Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in increased activity of LPL protein]; Proanthocyanidins inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in increased activity of LPL protein] |
CTD |
PMID:14684380 PMID:30273964 |
|
NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249
|
|
G |
Lrp2 |
LDL receptor related protein 2 |
increases expression multiple interactions |
ISO |
Cholic Acid results in increased expression of LRP2 protein NR1H4 protein promotes the reaction [Cholic Acid results in increased expression of LRP2 protein] |
CTD |
PMID:15375181 |
|
NCBI chr 3:54,189,305...54,346,769
Ensembl chr 3:54,189,308...54,346,708
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
increases expression |
ISO |
Cholic Acid results in increased expression of MAP1LC3B protein |
CTD |
PMID:24189133 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690 Ensembl chr16:49,665,791...49,677,690
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases activity |
ISO |
[Diethylnitrosamine co-treated with Cholic Acid] results in increased activity of and results in increased phosphorylation of MAPK1 protein Cholic Acid results in increased activity of MAPK1 protein |
CTD |
PMID:27151938 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases activity |
ISO |
[Diethylnitrosamine co-treated with Cholic Acid] results in increased activity of and results in increased phosphorylation of MAPK3 protein Cholic Acid results in increased activity of MAPK3 protein |
CTD |
PMID:27151938 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mcm3 |
minichromosome maintenance complex component 3 |
increases expression |
ISO |
Cholic Acid results in increased expression of MCM3 protein |
CTD |
PMID:20025956 |
|
NCBI chr 9:23,219,169...23,237,314
Ensembl chr 9:23,219,169...23,237,314
|
|
G |
Mgst3 |
microsomal glutathione S-transferase 3 |
increases expression |
ISO |
Cholic Acid results in increased expression of MGST3 mRNA |
CTD |
PMID:17521389 |
|
NCBI chr13:79,526,541...79,547,479
Ensembl chr13:79,526,541...79,547,411
|
|
G |
Mt1 |
metallothionein 1 |
increases expression |
ISO |
Cholic Acid results in increased expression of MT1 mRNA |
CTD |
PMID:17521389 |
|
NCBI chr19:10,826,032...10,827,048
Ensembl chr19:10,826,032...10,827,049 Ensembl chr17:10,826,032...10,827,049 Ensembl chr X:10,826,032...10,827,049
|
|
G |
Muc2 |
mucin 2, oligomeric mucus/gel-forming |
decreases expression |
EXP |
Cholic Acid results in decreased expression of MUC2 mRNA |
CTD |
PMID:35584729 |
|
NCBI chr 1:196,799,494...196,831,740
Ensembl chr 1:196,799,517...196,831,756
|
|
G |
Myl9 |
myosin light chain 9 |
increases phosphorylation |
EXP |
Cholic Acid results in increased phosphorylation of MYL9 protein |
CTD |
PMID:35584729 |
|
NCBI chr 3:145,281,943...145,288,333
Ensembl chr 3:145,281,937...145,288,333
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
increases expression |
ISO |
Cholic Acid results in increased expression of NFE2L2 mRNA |
CTD |
PMID:25582706 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
increases phosphorylation multiple interactions |
ISO |
Cholic Acid results in increased phosphorylation of NFKBIA protein Cholic Acid promotes the reaction [Diethylnitrosamine results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:27151938 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases expression |
ISO |
Cholic Acid results in increased expression of NQO1 mRNA |
CTD |
PMID:25582706 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr0b2 |
nuclear receptor subfamily 0, group B, member 2 |
multiple interactions increases expression |
EXP ISO |
[Cholesterol, Dietary co-treated with Cholic Acid] results in increased expression of NR0B2 mRNA Cholic Acid results in increased expression of NR0B2 mRNA [Cholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of NR0B2 mRNA; IL1B protein inhibits the reaction [Cholic Acid results in increased expression of NR0B2 mRNA] |
CTD |
PMID:12072388 PMID:14684380 PMID:15694933 PMID:16002565 PMID:16269825 PMID:22540009 PMID:24189133 PMID:25055961 PMID:25582706 More...
|
|
NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609
|
|
G |
Nr1h3 |
nuclear receptor subfamily 1, group H, member 3 |
multiple interactions |
EXP |
[Cholesterol, Dietary co-treated with Cholic Acid] results in increased activity of NR1H3 protein; [Cholesterol, Dietary co-treated with Cholic Acid] results in increased expression of NR1H3 mRNA; zingerone inhibits the reaction [[Cholesterol, Dietary co-treated with Cholic Acid] results in increased expression of NR1H3 mRNA] |
CTD |
PMID:14684380 PMID:33845646 |
|
NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
affects binding decreases expression increases phosphorylation increases expression multiple interactions increases activity |
ISO EXP |
Cholic Acid binds to NR1H4 protein Cholic Acid results in decreased expression of NR1H4 mRNA Cholic Acid results in increased phosphorylation of NR1H4 protein Cholic Acid results in increased expression of NR1H4 mRNA [Cholic Acid binds to and results in increased activity of NR1H4 protein] which results in decreased expression of CYP7A1 mRNA; [Cholic Acid binds to and results in increased activity of NR1H4 protein] which results in decreased expression of SLC10A1 mRNA; [Cholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of ABCB11 mRNA; [Cholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of NR0B2 mRNA; [Cholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of SCARB1 mRNA; [Cholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of SLC51B mRNA; [NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ABCA8 mRNA; [NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ABCA9 mRNA; [NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ABCB11 mRNA; [NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ABCG1 mRNA; [NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ABCG5 mRNA; [NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ABCG8 mRNA; [NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ATP8B1 mRNA; [NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of SCARB1 mRNA; Cholic Acid binds to and results in increased activity of NR1H4 protein; Cholic Acid promotes the reaction [SRC protein binds to NR1H4 protein]; Cholic Acid results in increased phosphorylation of and results in increased activity of NR1H4 protein; NR1H4 gene mutant form inhibits the reaction [Cholic Acid results in increased expression of SOD3 mRNA]; NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]; NR1H4 protein promotes the reaction [Cholic Acid results in increased expression of LRP2 protein] [[Cholic Acid results in increased activity of NR1H4 protein] which binds to FGF19 promoter] which results in increased expression of FGF19 mRNA; [Cholic Acid results in increased activity of NR1H4 protein] which binds to FGF19 promoter; Cholic Acid analog binds to and results in increased activity of NR1H4 protein; Cholic Acid binds to and results in increased activity of NR1H4 protein [Cholesterol, Dietary co-treated with Cholic Acid] results in increased activity of NR1H4 protein |
CTD |
PMID:13130122 PMID:14684380 PMID:15375181 PMID:15694933 PMID:19965603 PMID:22540009 PMID:22561792 PMID:25055961 PMID:25496033 PMID:29968724 PMID:30996006 PMID:35584729 More...
|
|
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases expression increases activity |
ISO |
Cholic Acid results in increased expression of NR1I2 mRNA Cholic Acid metabolite results in increased activity of NR1I2 protein; Cholic Acid results in increased activity of NR1I2 protein |
CTD |
PMID:25582706 PMID:27871908 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Orm1 |
orosomucoid 1 |
increases expression |
ISO |
Cholic Acid results in increased expression of ORM1 protein |
CTD |
PMID:20025956 |
|
NCBI chr 5:76,766,637...76,776,149
Ensembl chr 5:76,772,941...76,776,154
|
|
G |
Papss2 |
3'-phosphoadenosine 5'-phosphosulfate synthase 2 |
increases expression |
ISO |
Cholic Acid results in increased expression of PAPSS2 mRNA |
CTD |
PMID:17521389 |
|
NCBI chr 1:230,454,314...230,539,332
Ensembl chr 1:230,454,426...230,539,331
|
|
G |
Pcna |
proliferating cell nuclear antigen |
increases expression multiple interactions |
ISO |
Cholic Acid results in increased expression of PCNA protein [Diethylnitrosamine co-treated with Cholic Acid] results in increased expression of PCNA protein |
CTD |
PMID:27151938 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Pik3r5 |
phosphoinositide-3-kinase, regulatory subunit 5 |
increases expression |
ISO |
Cholic Acid results in increased expression of PIK3R5 protein |
CTD |
PMID:20025956 |
|
NCBI chr10:53,132,585...53,200,663
Ensembl chr10:53,132,603...53,199,374
|
|
G |
Pon1 |
paraoxonase 1 |
decreases expression multiple interactions |
ISO EXP |
Cholic Acid results in decreased expression of PON1 mRNA; Cholic Acid results in decreased expression of PON1 protein [Cholesterol co-treated with Cholic Acid] results in decreased secretion of PON1 protein; Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased secretion of PON1 protein]; Proanthocyanidins inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased secretion of PON1 protein] |
CTD |
PMID:16269825 PMID:30273964 |
|
NCBI chr 4:33,294,737...33,325,759
Ensembl chr 4:33,294,722...33,321,360
|
|
G |
Por |
cytochrome p450 oxidoreductase |
increases expression decreases abundance |
ISO |
Cholic Acid results in increased expression of POR mRNA POR gene mutant form results in decreased abundance of Cholic Acid |
CTD |
PMID:17521389 PMID:25034404 |
|
NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
decreases abundance multiple interactions |
ISO EXP |
PPARA gene mutant form results in decreased abundance of Cholic Acid [Cholesterol, Dietary co-treated with Cholic Acid] results in decreased expression of PPARA mRNA; zingerone inhibits the reaction [[Cholesterol, Dietary co-treated with Cholic Acid] results in decreased expression of PPARA mRNA] |
CTD |
PMID:29175453 PMID:33845646 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Rab7a |
RAB7A, member RAS oncogene family |
decreases expression |
ISO |
Cholic Acid results in decreased expression of RAB7 protein |
CTD |
PMID:24189133 |
|
NCBI chr 4:120,461,966...120,510,756
Ensembl chr 4:120,461,963...120,506,889
|
|
G |
Reg3b |
regenerating family member 3 beta |
decreases expression |
EXP |
Cholic Acid results in decreased expression of REG3B mRNA |
CTD |
PMID:35584729 |
|
NCBI chr 4:110,861,775...110,865,015
Ensembl chr 4:110,861,775...110,865,015
|
|
G |
Reg3g |
regenerating family member 3 gamma |
decreases expression |
EXP |
Cholic Acid results in decreased expression of REG3G mRNA |
CTD |
PMID:35584729 |
|
NCBI chr 4:110,922,805...110,927,803
Ensembl chr 4:110,924,168...110,926,723
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
Cholic Acid promotes the reaction [Diethylnitrosamine results in increased expression of RELA protein] |
CTD |
PMID:27151938 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rif1 |
replication timing regulatory factor 1 |
increases expression |
ISO |
Cholic Acid results in increased expression of RIF1 protein |
CTD |
PMID:20025956 |
|
NCBI chr 3:36,554,689...36,607,961
Ensembl chr 3:36,554,697...36,603,617
|
|
G |
Scarb1 |
scavenger receptor class B, member 1 |
multiple interactions |
ISO |
[Cholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of SCARB1 mRNA; [NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of SCARB1 mRNA |
CTD |
PMID:22540009 PMID:30996006 |
|
NCBI chr12:31,296,143...31,362,649
Ensembl chr12:31,296,156...31,362,647
|
|
G |
Slc10a1 |
solute carrier family 10 member 1 |
multiple interactions decreases expression |
ISO |
[Cholic Acid binds to and results in increased activity of NR1H4 protein] which results in decreased expression of SLC10A1 mRNA Cholic Acid results in decreased expression of SLC10A1 mRNA; Cholic Acid results in decreased expression of SLC10A1 protein |
CTD |
PMID:11438506 PMID:16002565 PMID:17521389 PMID:22540009 PMID:25055961 PMID:25582706 More...
|
|
NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670
|
|
G |
Slc10a2 |
solute carrier family 10 member 2 |
decreases expression affects expression |
ISO EXP |
Cholic Acid results in decreased expression of SLC10A2 mRNA Cholic Acid affects the expression of SLC10A2 mRNA Cholic Acid results in decreased expression of SLC10A2 protein |
CTD |
PMID:25582706 PMID:35584729 |
|
NCBI chr16:84,386,528...84,409,475
Ensembl chr16:84,374,862...84,409,475
|
|
G |
Slc22a20 |
solute carrier family 22 member 20 |
increases expression |
ISO |
Cholic Acid results in increased expression of SLC22A20 mRNA |
CTD |
PMID:17521389 |
|
NCBI chr 1:203,257,374...203,273,854
Ensembl chr 1:203,257,374...203,273,822
|
|
G |
Slc27a5 |
solute carrier family 27 member 5 |
multiple interactions |
ISO |
Cholic Acid inhibits the reaction [SLC27A5 protein results in increased uptake of Fatty Acids] |
CTD |
PMID:22531947 |
|
NCBI chr 1:73,616,556...73,627,149
Ensembl chr 1:73,616,564...73,627,172
|
|
G |
Slc2a1 |
solute carrier family 2 member 1 |
increases expression |
ISO |
Cholic Acid results in increased expression of SLC2A1 protein |
CTD |
PMID:20025956 |
|
NCBI chr 5:132,717,196...132,745,416
Ensembl chr 5:132,717,196...132,745,416
|
|
G |
Slc51a |
solute carrier family 51 member A |
increases expression |
ISO |
Cholic Acid results in increased expression of SLC51A mRNA |
CTD |
PMID:25055961 PMID:25582706 |
|
NCBI chr11:68,299,086...68,313,485
Ensembl chr11:68,299,086...68,313,485
|
|
G |
Slc51b |
SLC51 subunit beta |
multiple interactions increases expression |
ISO |
[Cholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of SLC51B mRNA Cholic Acid results in increased expression of SLC51B mRNA |
CTD |
PMID:22540009 PMID:22961653 PMID:25055961 PMID:25582706 |
|
NCBI chr 8:65,931,891...65,939,953
Ensembl chr 8:65,931,890...65,940,145
|
|
G |
Slco1a4 |
solute carrier organic anion transporter family, member 1a4 |
increases expression |
ISO |
Cholic Acid results in increased expression of SLCO1A4 mRNA |
CTD |
PMID:17521389 |
|
NCBI chr 4:174,710,004...174,764,810
Ensembl chr 4:174,710,004...175,254,573
|
|
G |
Slco1b2 |
solute carrier organic anion transporter family member 1B2 |
increases uptake increases expression |
ISO |
SLCO1B2 protein results in increased uptake of Cholic Acid Cholic Acid results in increased expression of SLCO1B3 mRNA SLCO1B3 protein results in increased uptake of Cholic Acid Cholic Acid results in increased expression of SLCO1B2 mRNA |
CTD |
PMID:16534140 PMID:20949553 PMID:25055961 PMID:25582706 |
|
NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981
|
|
G |
Slco2b1 |
solute carrier organic anion transporter family, member 2b1 |
multiple interactions increases uptake |
ISO |
Rutin promotes the reaction [SLCO2B1 protein results in increased uptake of Cholic Acid] |
CTD |
PMID:24285294 |
|
NCBI chr 1:153,959,288...154,007,294
Ensembl chr 1:153,959,293...154,007,353
|
|
G |
Sod3 |
superoxide dismutase 3 |
multiple interactions increases expression |
ISO |
NR1H4 gene mutant form inhibits the reaction [Cholic Acid results in increased expression of SOD3 mRNA] |
CTD |
PMID:25496033 |
|
NCBI chr14:58,610,104...58,615,845
Ensembl chr14:58,609,958...58,615,990
|
|
G |
Sqstm1 |
sequestosome 1 |
increases expression |
ISO |
Cholic Acid results in increased expression of SQSTM1 protein |
CTD |
PMID:24189133 |
|
NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Src |
SRC proto-oncogene, non-receptor tyrosine kinase |
multiple interactions |
ISO |
Cholic Acid promotes the reaction [SRC protein binds to NR1H4 protein] |
CTD |
PMID:29968724 |
|
NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions |
EXP |
[Cholesterol, Dietary co-treated with Cholic Acid] results in increased expression of SREBF1 mRNA; zingerone inhibits the reaction [[Cholesterol, Dietary co-treated with Cholic Acid] results in increased expression of SREBF1 mRNA] |
CTD |
PMID:33845646 |
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Stmn1 |
stathmin 1 |
increases expression |
ISO |
Cholic Acid results in increased expression of STMN1 protein |
CTD |
PMID:20025956 |
|
NCBI chr 5:146,680,757...146,687,154
Ensembl chr 5:146,681,436...146,687,154
|
|
G |
Sult2a1 |
sulfotransferase family 2A member 1 |
increases sulfation increases expression |
ISO |
SULT2A1 protein results in increased sulfation of Cholic Acid Cholic Acid results in increased expression of SULT2A1 mRNA |
CTD |
PMID:17521389 PMID:20102295 PMID:22961653 |
|
NCBI chr 1:75,451,178...75,508,113
Ensembl chr 1:74,911,100...75,508,134
|
|
G |
Tfrc |
transferrin receptor |
increases expression |
ISO |
Cholic Acid results in increased expression of TFRC protein |
CTD |
PMID:20025956 |
|
NCBI chr11:68,163,413...68,185,257
Ensembl chr11:68,163,413...68,185,257
|
|
G |
Tnf |
tumor necrosis factor |
increases expression multiple interactions |
ISO |
Cholic Acid results in increased expression of TNF mRNA Diethylnitrosamine promotes the reaction [Cholic Acid results in increased expression of TNF mRNA] |
CTD |
PMID:27151938 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnni3 |
troponin I3, cardiac type |
multiple interactions |
EXP |
[Cholesterol, Dietary co-treated with Cholic Acid] results in increased expression of TNNI3 protein; zingerone inhibits the reaction [[Cholesterol, Dietary co-treated with Cholic Acid] results in increased expression of TNNI3 protein] |
CTD |
PMID:33845646 |
|
NCBI chr 1:69,299,900...69,303,582
Ensembl chr 1:69,299,900...69,303,580
|
|
G |
Vdr |
vitamin D receptor |
increases localization |
ISO |
Cholic Acid results in increased localization of VDR protein |
CTD |
PMID:20371703 |
|
NCBI chr 7:128,987,981...129,037,677
Ensembl chr 7:128,987,981...129,037,677
|
|
G |
Vegfa |
vascular endothelial growth factor A |
increases expression |
ISO |
Cholic Acid results in increased expression of VEGFA protein |
CTD |
PMID:20025956 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
affects localization multiple interactions |
ISO |
dehydroeburicoic acid affects the localization of MAP1LC3B protein calpeptin inhibits the reaction [dehydroeburicoic acid affects the localization of MAP1LC3B protein]; calpeptin inhibits the reaction [dehydroeburicoic acid promotes the reaction [MAP1LC3B protein binds to phosphatidylethanolamine]]; dehydroeburicoic acid promotes the reaction [MAP1LC3B protein binds to phosphatidylethanolamine] |
CTD |
PMID:19848398 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690 Ensembl chr16:49,665,791...49,677,690
|
|
G |
Sptan1 |
spectrin, alpha, non-erythrocytic 1 |
multiple interactions increases degradation |
ISO |
calpeptin inhibits the reaction [dehydroeburicoic acid results in increased degradation of SPTAN1 protein] |
CTD |
PMID:19848398 |
|
NCBI chr 3:13,241,164...13,306,047
Ensembl chr 3:13,241,217...13,306,046
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions increases expression decreases expression |
ISO EXP |
SLCO1A1 protein affects the susceptibility to [Deoxycholic Acid results in decreased expression of ABCB11 mRNA] [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of ABCB11 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ABCB11 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of ABCB11 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ABCB11 mRNA Deoxycholic Acid results in increased expression of ABCB11 mRNA |
CTD |
PMID:14684751 PMID:21914718 PMID:25055961 PMID:27743861 PMID:32152650 PMID:33819548 More...
|
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases expression multiple interactions |
ISO |
Deoxycholic Acid metabolite results in increased expression of ABCB1 mRNA [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ABCB1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCB1 mRNA |
CTD |
PMID:27871908 PMID:33819548 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
affects expression multiple interactions increases expression |
ISO |
Deoxycholic Acid affects the expression of ABCB4 mRNA [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ABCB4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ABCB4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ABCB4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of ABCB4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCB4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ABCB4 mRNA Deoxycholic Acid results in increased expression of ABCB4 mRNA SLCO1A1 protein affects the susceptibility to [Deoxycholic Acid affects the expression of ABCB4 mRNA] |
CTD |
PMID:21914718 PMID:25582706 PMID:33819548 |
|
NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of ABCC1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of ABCC1 mRNA; Deoxycholic Acid inhibits the reaction [ABCC1 protein results in increased export of 2',7'-bis-(carboxypropyl)-5(6)-carboxyfluorescein] |
CTD |
PMID:16101123 PMID:33819548 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
multiple interactions affects expression |
ISO |
SLCO1A1 protein affects the susceptibility to [Deoxycholic Acid affects the expression of ABCC2 mRNA] [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of ABCC2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ABCC2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCC2 mRNA |
CTD |
PMID:21914718 PMID:33819548 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
increases activity multiple interactions decreases expression increases expression affects expression |
ISO |
Deoxycholic Acid results in increased activity of ABCC3 protein [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ABCC3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of ABCC3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ABCC3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCC3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ABCC3 mRNA Deoxycholic Acid results in decreased expression of ABCC3 mRNA Deoxycholic Acid results in increased expression of ABCC3 mRNA SLCO1A1 protein affects the susceptibility to [Deoxycholic Acid affects the expression of ABCC3 mRNA] |
CTD |
PMID:17569508 PMID:21914718 PMID:25055961 PMID:25582706 PMID:32152650 PMID:33819548 More...
|
|
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of ABCC4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of ABCC4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of ABCC4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ABCC4 mRNA |
CTD |
PMID:32152650 PMID:33819548 |
|
NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of ABCG2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of ABCG2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of ABCG2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of ABCG2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCG2 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Abcg5 |
ATP binding cassette subfamily G member 5 |
multiple interactions increases expression |
ISO |
SLCO1A1 protein affects the susceptibility to [Deoxycholic Acid results in increased expression of ABCG5 mRNA] [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ABCG5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ABCG5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ABCG5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ABCG5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCG5 mRNA |
CTD |
PMID:21914718 PMID:25055961 PMID:25582706 PMID:33819548 |
|
NCBI chr 6:9,965,118...9,990,563
Ensembl chr 6:9,965,118...9,990,563
|
|
G |
Abcg8 |
ATP binding cassette subfamily G member 8 |
multiple interactions increases expression |
ISO |
SLCO1A1 protein affects the susceptibility to [Deoxycholic Acid results in increased expression of ABCG8 mRNA] [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of ABCG8 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ABCG8 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ABCG8 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ABCG8 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ABCG8 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCG8 mRNA |
CTD |
PMID:21914718 PMID:25582706 PMID:33819548 |
|
NCBI chr 6:9,945,629...9,964,912
Ensembl chr 6:9,945,629...9,964,912
|
|
G |
Acsl1 |
acyl-CoA synthetase long-chain family member 1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ACSL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ACSL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ACSL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ACSL1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr16:45,755,246...45,821,541
Ensembl chr16:45,755,254...45,821,541
|
|
G |
Adgrg1 |
adhesion G protein-coupled receptor G1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of ADGRG1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of ADGRG1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of ADGRG1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of ADGRG1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of ADGRG1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ADGRG1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr19:10,003,963...10,041,122
Ensembl chr19:10,003,975...10,041,108
|
|
G |
Adh1c |
alcohol dehydrogenase 1C (class I), gamma polypeptide |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of ADH1C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ADH1C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ADH1C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ADH1C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ADH1C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ADH1C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ADH1C mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 2:226,797,303...226,808,892
Ensembl chr 2:226,797,303...226,808,892
|
|
G |
Adh4 |
alcohol dehydrogenase 4 (class II), pi polypeptide |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of ADH4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ADH4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ADH4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ADH4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ADH4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ADH4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ADH4 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 2:226,948,717...226,966,747
Ensembl chr 2:226,947,466...226,987,591
|
|
G |
Adh6 |
alcohol dehydrogenase 6 (class V) |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of ADH6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ADH6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ADH6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ADH6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ADH6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ADH6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ADH6 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 2:226,903,208...226,934,564
Ensembl chr 2:226,903,250...226,934,534
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
decreases expression |
ISO |
Deoxycholic Acid results in decreased expression of ADIPOQ mRNA |
CTD |
PMID:23911798 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions decreases abundance increases secretion |
ISO |
AHR gene mutant form inhibits the reaction [Tetrachlorodibenzodioxin results in decreased secretion of Deoxycholic Acid] AHR gene mutant form results in decreased abundance of Deoxycholic Acid AHR gene mutant form results in increased secretion of Deoxycholic Acid |
CTD |
PMID:29452137 PMID:32679164 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Akr1a1 |
aldo-keto reductase family 1 member A1 |
multiple interactions |
ISO |
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR1A1 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 5:130,092,945...130,130,277
Ensembl chr 5:130,092,732...130,113,674
|
|
G |
Akr1d1 |
aldo-keto reductase family 1, member D1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of AKR1D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of AKR1D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of AKR1D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of AKR1D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of AKR1D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of AKR1D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR1D1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 4:66,154,246...66,187,505
Ensembl chr 4:66,154,248...66,186,372
|
|
G |
Akr7a2 |
aldo-keto reductase family 7, member A2 |
multiple interactions |
ISO |
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of AKR7A2 mRNA |
CTD |
PMID:32152650 PMID:33819548 |
|
NCBI chr 5:151,552,375...151,560,914
Ensembl chr 5:151,552,343...151,560,909
|
|
G |
Akr7a3 |
aldo-keto reductase family 7 member A3 |
multiple interactions |
ISO |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of AKR7A3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of AKR7A3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of AKR7A3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of AKR7A3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA |
CTD |
PMID:32152650 PMID:33819548 |
|
NCBI chr 5:151,590,968...151,601,394
Ensembl chr 5:151,584,479...151,601,394
|
|
G |
Alb |
albumin |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of ALB mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ALB mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ALB mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ALB mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ALB mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ALB mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ALB mRNA |
CTD |
PMID:33819548 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Aldh1a2 |
aldehyde dehydrogenase 1 family, member A2 |
multiple interactions |
EXP |
[gluconic acid co-treated with Deoxycholic Acid] results in increased expression of ALDH1A2 mRNA |
CTD |
PMID:16556975 |
|
NCBI chr 8:71,877,850...71,957,107
Ensembl chr 8:71,877,850...71,957,107
|
|
G |
Alpp |
alkaline phosphatase, placental |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of ALPP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ALPP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ALPP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ALPP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ALPP mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 9:87,765,846...87,768,606
Ensembl chr 9:87,765,860...87,768,606
|
|
G |
Ampd3 |
adenosine monophosphate deaminase 3 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of AMPD3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of AMPD3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of AMPD3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of AMPD3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of AMPD3 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 1:164,884,823...164,929,899
Ensembl chr 1:164,885,320...164,929,887
|
|
G |
Aox1 |
aldehyde oxidase 1 |
multiple interactions |
ISO |
[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AOX1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AOX1 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 9:59,579,621...59,658,772
Ensembl chr 9:59,579,649...59,658,770
|
|
G |
Apoa1 |
apolipoprotein A1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of APOA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of APOA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of APOA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of APOA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of APOA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of APOA1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035
|
|
G |
Areg |
amphiregulin |
increases secretion |
ISO |
Deoxycholic Acid results in increased secretion of AREG protein |
CTD |
PMID:16213893 |
|
NCBI chr14:16,972,185...16,981,443
Ensembl chr14:16,972,187...16,981,535
|
|
G |
Arnt2 |
aryl hydrocarbon receptor nuclear translocator 2 |
multiple interactions |
EXP |
[gluconic acid co-treated with Deoxycholic Acid] results in increased expression of ARNT2 mRNA |
CTD |
PMID:16556975 |
|
NCBI chr 1:138,236,235...138,392,868
Ensembl chr 1:138,189,940...138,393,153
|
|
G |
Atf3 |
activating transcription factor 3 |
multiple interactions increases expression |
ISO |
MTF1 protein affects the reaction [Deoxycholic Acid results in increased expression of ATF3 mRNA] |
CTD |
PMID:32661532 |
|
NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631
|
|
G |
Atf4 |
activating transcription factor 4 |
multiple interactions |
ISO |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ATF4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
|
|
G |
Atf6 |
activating transcription factor 6 |
multiple interactions |
ISO |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177
|
|
G |
Atg7 |
autophagy related 7 |
multiple interactions |
ISO |
[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA |
CTD |
PMID:32152650 |
|
NCBI chr 4:147,718,663...147,925,656
Ensembl chr 4:147,718,752...147,925,593
|
|
G |
Atp6v1f |
ATPase H+ transporting V1 subunit F |
multiple interactions |
EXP |
[gluconic acid co-treated with Deoxycholic Acid] results in increased expression of ATP6V1F mRNA |
CTD |
PMID:16556975 |
|
NCBI chr 4:58,067,666...58,070,628
|
|
G |
Atp8b1 |
ATPase phospholipid transporting 8B1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ATP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ATP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ATP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ATP8B1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr18:58,016,382...58,157,213
Ensembl chr18:58,018,268...58,157,396
|
|
G |
Baat |
bile acid CoA:amino acid N-acyltransferase |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of BAAT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of BAAT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of BAAT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of BAAT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of BAAT mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 5:63,851,668...63,860,641
Ensembl chr 5:63,850,705...63,860,685
|
|
G |
Bach1 |
BTB domain and CNC homolog 1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of BACH1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr11:26,939,429...26,974,876
Ensembl chr11:26,939,480...26,972,447
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression multiple interactions |
EXP |
Deoxycholic Acid results in increased expression of BAX mRNA; Deoxycholic Acid results in increased expression of BAX protein [Deoxycholic Acid results in increased expression of CCND1 protein] which affects the localization of BAX protein; TP53 protein affects the reaction [[Deoxycholic Acid results in increased expression of CCND1 protein] which affects the localization of BAX protein]; Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in increased expression of BAX mRNA]; Ursodeoxycholic Acid inhibits the reaction [Deoxycholic Acid results in increased expression of BAX protein] |
CTD |
PMID:9562975 PMID:10510466 PMID:17431217 PMID:17881359 PMID:20137712 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases response to substance |
ISO |
BCL2 protein results in decreased susceptibility to Deoxycholic Acid |
CTD |
PMID:12507930 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions |
ISO |
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of BCL2L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of BCL2L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of BCL2L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of BCL2L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of BCL2L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of BCL2L1 mRNA |
CTD |
PMID:33819548 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479 Ensembl chr 1:141,253,523...141, |